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                                            ABSTRACT 
Introduction: Leishmaniasis is a major public health problem in several parts of 
the world. It is caused by the obligate intracellular protozoan parasite of the genus 
leishmania and is transmitted by the female sand fly of the genera phlebotomus 
and lutzomyia. It presents in different clinical forms: cutaneous (CL) diffuse 
cutaneous (DCL), Visceral (VL), mucocutaneous (MCL), mucosal (ML) or post 
kalazar dermal leishmaniasis (PKDL). Leishmaniasis is difficult to treat and there 
is increasing resistance developing against the currently available drugs which are 
toxic, expensive, given by injection and requires hospitalization for long duration.  
Objectives: The aim of this study was to identify and evaluate selected drugs 
used for treatment of other diseases for antileishmanial activity using comparative 
bioinformatics and in vitro human macrophage (THP1) infection assay.  
Methods: Basic Local Alignment Search Tool (BLAST) was used to determine 
protein homology of the target sequence of isoniazid in Mycobacterium 
tuberculosis and Leishmania parasites. Similar search was done to determine 
protein homology of target sequence of sulfadoxine pyrimehamine in Plasmodium 
and Leishmania parasites. 
 Based on the determined protein homology, antileishmanial activity of isoniazid, 
isoniazid plus sodium stibogluconate (SSG), isoniazid plus liposomal 
amphotericin B (AmBisome), sulfadoxine pyrimethamine combination was 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
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evaluated using in vitro human macrophage (THP1) infection assay. The data was 
statistically analyzed using paired sample t test. 
Results: Alignment of isoniazid target sequence in mycobacterium tuberculosis 
and leishmania major and donovani showed 50% maximum identities while 
alignment of Sulfadoxine pyrimethamine target sequence in plasmodium 
falciparum and Leishmania donovani and Leishmania major showed 53% 
maximum identities.  
Significant antileishmanial activity of isoniazid against both Leishmania major 
and Leishmania donovani at 0.1, 0.2 and 0.4µg/ml concentrations was detected by 
decreasing the number of amastigotes compared to the negative control. 
Significant synergistic effect when isonaizid was used in combination with 
sodium stibogluconate and with liposomal amphotericin B was detected by 
increasing the percentage of killing compared with that of each drug alone.  
Sulfadoxine pyrimethamine combination showed minimum antileishmanial 
activity at 1.9 pyrimethamine and 38.1 sulfadoxine, 2.9 pyrimethamine and 57.1 
sulfadoxine, 3.8 pyrimethamine and 76.2 sulfadoxine concentrationscompared 
with SSG. 
Conclusion: Isoniazid showed significant antileishmanial activity and 
significantly enhanced the antileishmanial effect of SSG and amBisome, while 
Sulfadoxine pyrimethamine combination had minimum antileishmanial activity.  
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1.1. INTRODUCTION AND LITERATURE REVIEW  
Leishmaniasis is a major public health problem in several parts of the world. It is 
a group of diseases endemic in 88 countries in Asia, Africa, Europe and Latin 
America. The annual incidence of cutaneous leishmaniasis is estimated at 1.5 -2 
millions and 500.000 new cases of visceral leishmaniasis are estimated (WHO 
2004). Both the geographic distribution and case numbers are reported to be on 
increase (WHO 2000).  
Leishmaniasis is caused by the obligate intracellular protozoan parasite of the 
genus leishmania and is transmitted by the female sand fly of the genera 
phlebotomus and lutzomyia (Elnaiem et al., 1998; Molyneux and Ashford, 1983). 
It presents by different clinical forms: cutaneous (CL), diffuse cutaneous (DCL), 
Visceral (VL), mucocutaneous (MCL), or mucosal (ML) and post kalazar dermal 
leishmaniasis (PKDL). In CL and MCL the parasites generally remain restricted 
to the skin or skin and mucosa respectively. CL lesions may persist for long 
periods, but tend to heal spontaneously, whereas a greater tendency to destructive 
changes is seen in MCL infections. In contrast, in VL the leishmania organisms 
can invade the entire mononuclear phagocytic system in various organs (spleen, 
liver, lymph nodes, bone marrow, blood monocytes, etc.), causing infections that 
are normally lethal without treatment. The course of an infection is apparently 
dependent on the activation of various T lymphocyte subpopulations by 
Leishmania antigens. Activation of TH1 cells involves production of IFN? , which 
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activates macrophages that exert a protective effect by killing Leishmania 
organisms by nitric oxide (NO) mediated mechanism. On the other hand, when 
TH2 cells are activated large amounts of IL-4 and IL-10 are produced, which 
inhibit NO activity, thus reducing or even preventing elimination of the parasites. 
In CL, high concentrations of IFN?  were produced while in severe cases of VL 
the levels of IL-4 and IL-10 were high and IFN?  concentration was low. The 
situation is similar in severe forms of MCL. 
Diagnosis of leishmaniasis is based on direct demonstration of leishmania 
parasites on smears made from aspirate from cutaneous lesions or lymphoid 
organs. (Weiss, 1995; Osman et al.,1997), several immunological methods such 
as enzyme linked immunesorbent assay (ELISA), the direct immunoflourescent 
antibody test (IFAT) (Zuckerman, 1975) and direct agglutination test (DAT) 
(Harith et al., 1986), were developed and used for diagnosis of leishmaniasis. 
Polymerase chain reaction (PCR) amplification of parasite DNA is widely used 
technique for diagnosis and characterization of leishmania species (Chance et al., 
1974).  Leishmaniasis is difficult to treat and there is increasing resistance 
developing against the currently available drugs (Davidson, 1999). Sodium 
stibogluconate (SSG) is the first line of treatment of visceral leishmaniasis in 
Sudan. Liposomal amphotericin B is the second line treatment.  Other drugs such 
as meltifosine and paromomycin are under evaluation. 
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1.1.1 Clinical forms of leishmnaiasis   
Specific clinical manifestations are generally associated with particular 
leishmania species, but different clinical forms can be caused by the same species. 
1.1.1.1 Cutaneous leishmaniasis (CL)  
Cutaneous leishmaniasis (CL) in Sudan is caused by Leishmania major and 
Leishmania donovani (Elamin et al., 2008). The disease is endemic in many parts 
of the country. Clinically CL patients usually present with papules, nodules or 
noduloulcerative lesions mainly on the exposed parts of the skin, particularly the 
limbs. The face is less frequently affected. Lesions on the face are more 
frequently encountered in children than in adults. Other sites affected include the 
trunk and less commonly the scalp, buttocks, eyelids and genitalia. (Elhassan and 
Zijlstra, 2001).This is the simplest form of the disease and can heal spontaneously 
but can persist for many years.  
1.1.1.2 Diffuse cutaneous leishmaniasis (DCL)  
It is a disfiguring but a rare form of cutaneous disease. It is characterized by 
multiple non-ulcerative nodules or plaques. This form of the disease does not self 
heal and is very difficult to treat (Bryceson, 1996). 
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1.1.1.3 Visceral leishmaniasis (VL)  
Visceral leishmaniasis, also known as (Kala-Azar), has been among the most 
important health problems in Sudan. The main endemic focus extends from the 
Upper Nile state, north to the White Nile state, east to the Blue Nile and north east 
to Gadarif State. The global incidence of VL is estimated to be 0.5 millions, 90% 
of VL cases occur in Bangladesh, Brazil, India and Sudan (Desjeux, 2004). 95% 
of VL patients die resulting in at least 500,000 deaths per year worldwide.  It is 
the most severe form of leishmaniasis and it has a mortality rate of almost 100% 
within one year (Desjeux 2004). 
Visceral leishmaniasis in Sudan is caused by leishmania donovani; the disease is 
characterized by chronic fever, weakness, weight loss, hepatosplenomegaly, 
lymphadenopathy and anemia.  
1.1.1.4 Post kala-azar dermal leishmaniasis (PKDL) 
Visceral leishmaniasis may develop after the treatment into dermatosis commonly 
known as post kala-azar dermal leishmaniasis (PKDL) which is characterized by 
skin rashes and lesions. In Sudan 56%-62% of VL patients who have been 
successfully treated for VL develop PKDL (Elhassan and Zijlstra, 2001). In about 
15% of PKDL cases the disfiguring lesions persist sometimes for many years. 
Although the lesions heal spontaneously after few weeks, the lesions can lead to 
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severe facial scarring leading to social stigma confused with leprosy (Musa et al., 
2005).    
1.1.1.5 Mucocutaneous leishmaniasis (MCL)  
The term mucosal leishmaniasis is used in Sudan rather than mucocutaneous 
leishmaniasis. Sudanese mucosal leishmaniasis is chronic infection of upper 
respiratory tract and /or oral mucosa caused mainly by L.donovani and less 
frequentely by L.major (Ghalib et al., 1992). The disease occurs in areas of the 
related country endemic for VL particulary among Masalit and other closely 
tribes in western Sudan (Elhassan and Zijlstra, 2001).   
The symptoms depend on the location of the lesion. Patients may present with 
pain, but this is usually mild. Those with nasal leishmaniasis complain of nasal 
obstruction, discharge, bleeding and deformity of the nose. Patient with oral and 
pharyngeal disease have a sensation of fullness in the mouth and may have 
difficulty in mastication and swallowing. Bleeding may occur particularly when 
the gums are affected. Toothache may be the first symptom. The teeth may 
become loose and are sometimes shed spontaneously (Abbas et al., 1992). 
Hoarseness of voice, bleeding and cough occur when the larynx is affected.    
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Fig (1): Distribution of leishmaniasis in Sudan and South Sudan adopted from 
edoc.hu.berlin.de. (# Endemic areas of visceral, \\\ endemic areas of cutaneous 
leishmaniasis).   
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1.1.2 The life cycle of leishmania parasite   
In human and other vertebrates, leishmania resides in phagocytic cells 
(macrophages, monocytes and langerhans cells) as amastigote form which is 
round to oval in shape, 2-5 µm in diameter with a nucleus and rod shaped 
kinetoplast. The amastigote stages of the parasite is ingested by the sand flies 
(Phlebotomus oriental and Phlebotomus papatasi) (Ashford et al., 1992; Elnaiem 
et a.,l 1998) with blood meal, then transforms  in the fly gut into slender flagellate 
promastigote forms 10-15µm long which multiply and migrate back into 
proboscis. 
When infected sand flies take another blood meal, the promastigote forms are 
inoculated into new hosts. In the mammalian host the promastigotes invade 
macrophages, and then they transform into amastigote form and reproduce by 
binary fission. The amastigotes are then released from macrophages by exocytosis 
(Molyneux and Killick-Kendrick, 1987). 
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Fig (2): life cycle of leishmania parasites adopted from niaid.nih.gov 
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1.1.3 leishmania parasite and macrophage interaction 
Leishmania parasite has a number of surface molecules that play important roles 
in host parasite interaction such as the attachment and the uptake of the parasite 
by the macrophage. These are the acid phosphate and the lipophosphoglycans 
(LPG) such as glycoprotein GP63. The LPG is restricted to the promastigotes. It 
protects the promastigotes from host complement lysis and it has role in the 
establishment of the parasite in the macrophage (Mc Conville and Blackwell, 
1991). When the infective promastigotes injected into the host dermal tissue, they 
generate chemotactic activity for monocytes via GP63 by activating the 
complement with production of C5a and C3b (Sorensen et al., 1989; Bryceson, 
1996). C3b is deposited on the parasite surfaces and is recognized by a 
macrophage receptor (Wilson and Pearson, 1988). The promastigote's GP63 is 
involved in the binding of promastigotes to macrophage through a receptor-
mediated mechanism.  The macrophage receptors that are involved are; the 
complement receptors (CR1) and (CR3) (Talamas-Rohana et al., 1990). CR3 
binds directly to GP63, which has been shown to be the receptor for the 
promastigote surface glycoprotein, GP63 (Russel and Wright, 1988).  In addition, 
mannose-fucose and lectin-like receptors play major role in the attachment of the 
parasite to the macrophage surface (Blackwell et al., 1985).  Then the 
promastigotes will be taken up by macrophages and transform into amastigotes 
which are internalized in the phagosome and then the lysosome of the 
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macrophage fuses with the phagosome to form a phagolysosome containing the 
parasite.  
1.1.4 Treatment of leishmaniasis  
Sodium stibogluconate (SSG) is the classic treatment of all forms of leishmaniasis 
(Berman 2003). Liposomal amphotericin B is very potent agent for visceral 
leishmaniasis. Additional antileishmanials include paromomyin, miltefosine and 
others. 
1.1.4.1 Sodium stibogluconate (SSG) 
SSG is a pentavalent antimonial and it is the classic treatment for all forms of 
leishmaniasis, including the cutaneous disease. To be absorbed, antimonials must 
be delivered parentrally, either intravenously or intramuscularly. The standard 
dose for New World cutaneous disease is 20 mg antimony/kg/day for 20 days. 
The treatment needed for cutaneous disease is non parenteral therapy, or a shorter 
course of parenteral therapy both of which are more appropriate than 20 days of 
antimony injections for this ultimately self healing skin ulcer. The standard dose 
for visceral disease is 20 mg antimony /kg/day for 28 days (Berman 2003). 
Antimonials are known to inhibit glycolytic enzymes and fatty acids oxidation in 
amastigote form. Severe side effects were reported such as pancreatitis which is 
the cause of nausea and abdominal pain experienced by many patients. Other side 
effects include pancytopenia, peripheral neuropathy and cardio toxicity (Brummit, 
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1996). These compounds continued to be used successfully to treat millions of 
patients throughout the world for almost half century, but reports of 
unresponsiveness to the standard 10 mg /kg body weight of SSG started in 1970s. 
However, the disease remained treatable with higher doses of SSG 20mg/kg body 
weight but many cases were reported to have developed resistance (Thakur et al., 
1991). 
1.1.4.2 Amphotericin B  
It is antifungal agent discovered in 1956 from a bacterium of genus streptomyces. 
Amphotericin B binds to cell wall sterols but preferentially to ergosterol which is 
the major cell memberane sterol of fungi as well as leishmania. Amphotericin B 
has been given to large number of patients with kala-azar who were clinically 
resistant to SSG and pentamidine. In India 99% of patients were cured with 
standard regimen of 20 injections (1mg/kg alternate day (AD)) of amphotericin B 
(Mishra, 1992). Amphotericin B has infusion related side effects such as fever, 
chills, bone pain, cardiac arrest and delayed side effects such as hypokalaemia and 
nephrotoxicity (Berman, 1997; Sundar, 2001). These undesirable effects are 
reduced by association of Amphotericin B with the liposomes (liposomal 
Amphotericin B; Ambisome ;) (Singh and Sivakumar, 2004). This association not 
only reduces the drug toxicity but also increases their efficiency and concentration 
in tissues. Liposomal amphotericin B is a very potent agent for visceral 
leishmaniasis and is the drug of choice for antimony resistant disease. But 
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unfortunately the production is very expensive which make their use difficult in 
poor country (Golenser et al., 1999).   
1.1.4.3 Paromomycin 
Paromomycin (aminosidine) is aminoglycoside used for the treatment of bacterial 
diseases. However, it has been found to have broad antiparasitic activity not 
shared with other aminoglycosides. Injecetable paromomycin is used for visceral 
leishmaniasis at dosage of 14-16 mg/kg/day given for up to 3 weeks. 
Paromomycin at a dose of 16 mg/kg/day for 21 days cured 24 out of 27 (89%) 
Indian patients with visceral disease, in a region where there was antimony 
resistance such that a concomitant antimony treated group had a 69% cure rate 
(Thakur et al., 2000). But hence as an amino glycoside, it has the potential risk for 
renal toxicity and eighth cranial nerve toxicity.  
1.1.4.4 Miltefosine 
Miltefosine is alkyl phosoholipid which was developed as anti tumor agent. It 
stimulates the hematopoietic and immune system, with T cells and macrophage 
activation and with the increase of the interferon-?  production, thus helping 
against Leishmania infection (Escobar et al., 2001), therefore has recently been 
approved for the treatment of visceral leishmaniasis in adult at dose of 100 mg 
(2.5 mg /kg) for 4 weeks. It is also being used in the treatment of cutaneous 
leishmaniasis. Preclinical studies using the same dosage as for anticancer 
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treatment indicated that the drug had teratogenic effects, renal toxicity and 
adverse effects on fertility in males. The dosage of the drug required for the 
treatment of VL is however far less than that required for management of cancer 
and consequently has reduced adverse reactions. The result of phase III clinical 
trials of miltefosine in India have shown that this oral drug is very effective for 
treating VL in both  adults and children and has limited side reaction (Berman,  
2003).   
1.1.4.5 Pentamidine 
This drug was primarily used for treating Pneumocystis carinii pneumonia. The 
exact mechanism of action of pentamidine isethionate is not known, but some 
workers hypothesized that this polyamine compound acts on the kinetoplast DNA 
and inhibits its functions (Singh and Sivakumar, 2004). The pentamidine 
treatment was successfully used in the late 1970s and early 1980s and a cure rate 
of 98.8% was reported without any relapse (Jha, 1983). The regimen consisted of 
4mg/kg given three times a week for 3–4 weeks (10–12injections). However, the 
success rate started declining in the 1980s when even after 20 injections only 
75.2% of patients were cured (Thakur et al., 1991). The repeated administration 
of 2 mg pentamidine isethionate/kg every other day for 7 days was studied for the 
treatment of cutaneous disease in Colombia. This regimen was 96% effective. To 
decrease the dosing further, 2 mg/kg pentamidine was administered every other 
day for only 4 days, but this decreased the cure rate to 84%. However, a slightly 
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higher dose (3 mg/kg/IM) administered on 4 alternate days resulted in a 96% cure 
rate for 51 evaluable patients (Soto et al., 1994). The low-dose, short-course 
regimens for cutaneous leishmaniasis commonly result in myalgias, pain at the 
injection site, nausea, headache and less commonly result in a metallic taste, a 
burning sensation, numbness, and hypotension. Reversible hypoglycemia 
occurred in about 2% of cases. The incidence and severity of these side effects are 
higher when the high dose, long course regimens are used for treatment of 
visceral disease.  
Because of the high rate of toxicity of pentamidine and recent reports of 
emergence of drug resistance, this drug is rarely being used for visceral disease. 
For cutaneous disease, the high cure rate associated with a low dose of 
pentamidine given for a short period makes it an attractive alternative to SSG and 
the treatment of choice in cases of fresh cases as well as SSG treatment failure 
cases (Berman, 1997).  
1.1.4.6 Cytokines 
Human recombinant interferon-?  was used as an adjunct antimony therapy for 
visceral leishmaniasis (Badaro et al., 1990). These investigators found that seven 
of nine cases of SSG resistant kala-azar could be cured with the combination of 
interferon ?  given for 28 days. A subsequent trial showed that interferon ?  was 
only partially effective by itself. It was found that interferon ? , in combination 
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with SSG, could speed the elimination of parasites in previously untreated 
patients (Sundar and Murray, 1995). 
1.1.4.7 Allopurinol  
Allopurinol was the first oral antileishmanial. This hypoxanthine analogue 
inhibits purine catabolism in mammalian cells and purine anabolism in 
Leishmania. It works on the principle that Leishmania species are unable to 
synthesize purines. Allopurinol is hydrolyzed to allopurinol riboside, an analogue 
of inosine that is incorporated instead of ATP into leishmanial RNA. There it 
interferes with the normal protein synthesis of the parasite (Singh and Sivakumar, 
2004). Although allopurinol has been used to treat leishmaniasis for decades, a 
recent placebo-controlled double blinded trial in Colombian patients of cutaneous 
leishmaniasis caused by L.panamensis showed that allopurinol (20mg/kg/day for 
28days) was no better than placebo. It was concluded that allopurinol 
monotherapy is ineffective against Colombian cutaneous disease and therefore is 
unlikely to be effective against other forms of leishmaniasis (Berman, 1997).  
1.1.4.8 Imidazole derivatives 
Metronidazole and other imidazole derivatives as well as several other oral drugs 
have been studied as antileishmanial agents (Mishra and Thakur, 1985). The 
principle quoted for using imidazoles as antileishmanial drugs is that the sterol 
composition of Leishmania species is similar to that of yeast and other fungi. 
Metronidazole eliminates only 30% of the parasites even when used at its peak 
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serum levels (30µ g/ml) after intravenous administration. However, ketoconazole 
was found effective against Leishmania (Singh and Sivakumar, 2004). 
Hydrolyzed ketoconazole is the most effective drug that eliminated all parasites at 
a dose of 3.0 µ g/ml and 80%–95% of the parasites at drug concentrations that are 
achievable. However, other derivatives such as miconazole and cotrimazole are 
found ineffective or toxic (Wali et al., 1992). The effective dose of ketoconazole 
for cutaneous patients is 400mg/day for 28 days and for kala azar patients is 600 
mg/day for 28 days. 
The common side effect of ketoconazole is hepatotoxicity. Less commonly are 
endocrine dysfunction, reduction in cortisol levels and hypoadrenalism (Wali et 
al., 1992).  
 
1.1.4.9 Combination therapy  
After increasing unresponsiveness to most of the monotherapeutic regimens, the 
combination therapy has found new scope in the treatment of both cutaneous and 
visceral leishmaniasis (Das et al., 2001). Recently, combination therapy of  
sodium stibogluconate and indolylquinoline derivative A [2–2(2-
dichloroacetamidobenzyle)-3-(39-indolylquinoline)] showed 100% clearance of 
the parasites from liver and spleen of the hamsters as compared to 93% and 80%, 
respectively, when indolylquinoline derivative A and SSG were used singly (Pal 
et al., 2002). Similarly, the combination of low dosage pentamidine and 
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allopurinol was more effective in achieving an ultimate cure in 91.25% of kala-
azar patients as compared to 74.35% using pentamidine alone (Becker et al., 
1999). All monotherapies of cutaneous leishmaniasis are less effective as 
compared to topical paromomycin plus methylbenzethonim chloride, curing 
85.7%–91.4% cases. Other drugs tried are atovaquone, roxithromycin, and 
edelfosine. Drugs that have a long half-life and low therapeutic ratio, e.g., 
miltefosine, may induce drug resistance; therefore, such drugs should be used 
only in combination with another drug that has a short half life and greater 
therapeutic ratio (Bryceson, 2001).  
1.1.5 Bioinformatics, the application of computational techniques to analyze the 
information associated with biomolecules on a large scale, has become an 
increasingly useful tool in molecular biology researches, both for genomic and 
proteomic analysis. In this study, the application of computational methods is 
used to identify sequence homology of drug target gene between leishmania 
species and other selected pathogens. This was feasible because of the 
accessibility of whole genome sequence and suitable software programs for 
homology search.  
1.1.6 Leishmania genome 
Leishmania species are diploid organism having a relatively small genome 
(approximately 34 Mb). Leishmania genome has high GC content (63%) , it 
contains 36 chromosomes pairs ranging in size from 0.3Mb to 2.5 Mb containing 
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about 8,000 predicted genes (Myler et al., 2000). These genes are organized in 
tandom arrays or at least have two copies spreading through the genome. 
The mitochondrial DNA of the kinetoplastida (kDNA) which constitutes 
10%? 20% of the total DNA is mainly used as diagnostic tool to detect small 
amounts of parasite DNA in the biological material because of its highly 
repetitive nature (Barker, 1989).  
1.1.7 Homology methods and sequence alignments  
The bioinformatics identification of orthologos depends on sequence homology 
since similar sequence implies similar function. An array of bioinformatics 
techniques is available but I have selected basic local alignment search tool which 
is profile based algorithm for homologous sequence search. It finds regions of 
similarity between biological sequences, compares nucleotides or protein 
sequences to databases sequences and calculates the statistical significance of the 
matches. The net result was the selection of the following drugs:  
Isoniazid 
It is the most active drug for treatment of tuberculosis caused by susceptible 
strains. It acts by inhibiting the synthesis of mycolic acids, which are essential 
components of mycobacterial cell walls. It exerts its lethal effect by forming a 
covalent complex with an acyl carrier protein (AcpM) and KasA, a beta - ketoacyl 
carrier protein synthetase, which blocks mycolic acid synthesis.  
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Sulfadoxine and pyrimethamine combination 
Sulfadoxine; hence is a sulfonamide; interferes with folic acid synthesis via 
inhibition of dihydrofolic acid formation from para-aminobenzoic acid. 
Pyrimethamine inhibits dihydrofolic acid reduction to tetrahydrofolate resulting in 
sequential inhibition of enzymes of folic acid pathway. This combination is 
widely used as second line treatment of malaria.  
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1.2 RATIONALE  
Most of current antileishmanial agents are toxic, expensive, given by injection; 
require hospitalization for long duration with evidence of emergence of parasite 
resistance to several antieshmanial drugs. The successful completion of the 
leishmania whole genome sequencing provide an excellent opportunity for 
identification of new drug targets for production of safe, effective and affordable 
drugs.  The fact that drugs used for treatment of some diseases are effective 
against unrelated pathogen is encouraging to search of similar findings.  
1.3 OBJECTIVES 
General objectives:  
To identify and evaluate selected drugs used for treatment of other diseases for 
antileishmanial activity using comparative bioinformatics. 
Specific objectives:  
 1-To determine the DNA and / or protein sequence homology of known 
pathogens targeted by known drugs with the sequence of the Leishmania species.  
 2-To evaluate the sensitivity of the selected drugs against leishmania using in 
vitro drug sensitivity assay. 
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2.1 Materials   
Parasites 
Leishmania donovani                    (institute of endemic diseases) 
Leishmania major                          (institute of endemic diseases)    
Macrophage cell line 
THP1                                              (institute of endemic diseases)    
Media 
NNN agar                                   (Sigma Aldrich; Germany)    
DMEM                                      (Sigma Aldrich; Germany) 
Drugs 
Isoniazid                                   (Sigma Aldrich; Germany) 
AmBisome                               (Gilead science LTD; Ireland)  
Sodium stibogluconate             (Albert David LTD; India) 
Sulfadoxine pyrimethamine combination (Efroze chemical industries; Pakistan) 
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2.2 Methods 
2.2.1 Selection of candidate drugs 
Isoniazid and combination of sulfadoxine and pyrimethbamine were selected 
based on their mode of action on mycobacterium tuberculosis and plasmodium 
parasite respectively. 
2.2.3 Identification of pathogen target sequence for the selected drug  
Isoniazid inhibits the enzyme fatty acid synthase of the mycobacterium, 
sulfadoxine inhibits the enzyme ptreoate synthase and pyrimethamine inhibits the 
enzyme dihydrofolate reductase of the plasmodium. The protein sequence of these 
enzymes was retrieved from the database (protein database of ncbi.nlm.nih.gov). 
2.2.4 Alignment of the pathogen target sequence with leishmania sequence 
Leishmania sequence of these enzymes was retrieved from the database (protein 
database of ncbi.nlm.nih.gov) and aligned with the pathogen target sequence. 
Homology between leishmania sequence and pathogen sequence was determined 
using basic local search alignment tool (BLAST).  
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2.2.4 Evaluation of the antileishmanial activity of the candidate drugs on 
leishmania using THP1 macrophage cell line 
Two leishmania species were used in this study L.donovani which was isolated 
from lymph node aspirate of VL patient from Gadaref state and L.major which 
was isolated from skin lesion of CL patient from Khartoum state. The 
promastigotes of the two species were used for in vitro THP1 macrophage cell 
line infection. 
2.2.4.1 Parasite isolation and culture 
Leishmania parasites were isolated and incubated at 26°c in NNN agar tubes. 
Three days after incubation, smears were prepared to ensure the growth and check 
of contamnation. The primary cultures were sub cultured in freshly prepared 
biphasic media. 
 When parasite growth was established, the promastigotes were sub cultured in a 
sterile DMEM media supplemented with 10% heat inactivated fetal calf serum 
and 1% antibiotics (pencillin5000 IU/ml and streptomycin 5mg/ml). The cultures 
were incubated at 26°c. The cultures were examined using the inverted 
microscope to monitor growth and contamination every 2 days. Growing 
leishmania promastigotes were sub cultured in complete media and incubated at 
26°c for 7 days. Under these culture conditions the stationary growth phase was 
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reached. Giemsa stained smears were prepared and examined to check for the 
purity of the culture.   
2.2.4.2 Molecular characterization of the isolates 
2.2.4.2.1DNA extraction using Chelex method 
Growing promatigotes were harvested by centrifugation at 13000 rpm for 5 
minutes; the pellets were used for DNA extraction.   
Two hundred micro liters (200 µL) of well mixed 5%(W/V) chelex-100 slurry 
was transferred into two sterile micro centrifuge tubes 100 µL in each, which 
were heated at 100°C for 5 minutes by placing in the heating block of PERKIN 
ELMER DNA thermal cycler (480 USA). Hundred micro liters (100 µL) of 
L.donovani pellets was added into one tube and 100 µL of L .major pellets was 
added into the second tube. The mixtures were further heated at 100°C for 10 
minutes, and then centrifuged at 13000 rpm for 3 minutes. The upper layer was 
transferred into new tubes for polymerase chain reaction.  
2.2.4.2.2Polymerase chain reaction (PCR) 
Kinetoplast DNA (KDNA-PCR)  
KDNA-PCR was done using genus specific primers for mini circle kinetoplast 
DNA (kDNA) the AJS3, 5'ggggTTggTgTAAAATAgggC-3' and DBY 
5'CCAGTTTCCCgCCCCggAg-3’ primers. The reaction volume was 50µL per 
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sample in 0.5 ml thin walled micro centrifuge tube. The mixture consisted of 2.5 
µL 10x reaction buffer, 1.5 µL of 20mM dNTPs mix (ABgene-0196-UK), 2.0 µL 
of 25 mM MgCl2, 2.0 µL of each primer (10 mM each) and 0.3 µL of thermo 
stable DNA polymerase (5U/ µL). For each tube of PCR, 4 µL of template DNA 
were added; PCR mixture was completed to 25 µL with double distilled water. 
The reaction mixture was overlaid with 25 µL mineral oil. PCR was done using 
advanced primus (PEQ lab) PCR machine. The amplification was done for 35 
cycles. The DNA was initially denatured at 94 °C for 3 minutes. Each cycle 
included annealing at 64°C for 1 minute, extension at 72 °C for 1 minute and 
denaturation at 94°C for 3 seconds. A final extension cycle at 72°C for 10 minutes 
was run. The PCR products were analyzed for quantity and quality using the nano 
drop spectrophotometer and stored at 4 °C until analyzed by agarose gel 
electrophoresis. 
2.2.4.2.3PCR product analysis 
Agarose gel electrophoresis 
1.5% agarose gel was prepared by dissolving 1.5 gm of agarose in 100 ml 10% 
Tris Boric EDTA (TBE) with heating. After the dissolution of the agarose, 3 µL 
of 10 mg/ml ethidium bromide was added to the gel and mixed. The mixture was 
poured into horizontal electrophoresis mini gel tank with a suitable size combs 
and the gel was left for 1 hour to polymerize. 7 µL of PCR product were mixed 
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with 7 µL of the loading buffer and loaded into the wells. 5 µL of DNA molecular 
weight marker was loaded into a separate well. Running buffer which consists of 
1.5 ml 10% TBE and 250 ml distilled water was added. Electrophoresis was run 
for 1 hour at 70 volt and the current ranges from 3 to 5. The gel was visualized 
over ultra violet transilluminater (ANACHEM UK) and photographed using gel 
documentation system (SYNGENE BIOIMAGING system).  
2.2.4.3Media preparation 
2.2.4.3.1 Preparation of NNN media 
The modified NNN media consisted of solid and liquid phase. The solid phase 
was prepared by dissolving 2.5 gm blood agar base in 100 ml distilled water. The 
mixture was then boiled, autoclaved and cooled to 50°c. 10 ml of rabbit blood 
was taken and into tube containing glass beads then it was shacked for 15 minutes 
to remove the fibrinogen. The defibrinated blood was added to the mixture. 1% of 
Antibiotic mixture consisting of 5000 IU/ml penicillin and 5 mg/ml streptomycin 
was added. Then the media was liquated into sterile glass tubes that were laid in a 
slope position till the agar solidified. The tubes were incubated at 4°c for 24 hours 
and the liquid phase consisting of 10% fetal calf serum and 90% CM was added 
to the media just before use. 
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2.2.4.3.2 Preparation of the complete media (CM) 
17.3 gm Dulbecco’s modified eagle’s medium (DMEM) with L- glutamine, 4500 
mg glucose and 25 Mm HEPES PH 7.4 was dissolved in 1L distilled water using 
magnetic shaker. Then 3.7 gm NaHCO3 was added and the pH was measured 
using pH meter and adjusted to 6.1?  6.3 using 1N NaOH or 1N HCL, the media 
was filtered using filter membrane of 0.22 µ porosity. 10% heat inactivated fetal 
calf serum and 1% antibiotic mixture (5000 IU/ml penicillin and 5 mg/ml 
streptomycin) were added. 
2.2.4.3.3 Preparation of the freezing media 
10 ml of sterile glycerol, 30 ml of Dulbecco’s modified eagle’s medium (DMEM) 
and 60 ml of heat inactivated fetal calf serum were mixed together to produce 100 
ml freezing media. 
2.2.4.4 Preparation of the stains 
2.2.4.4.1 Preparation of Giemsa stain stock solution  
Giemsa’s solution is a mixture of methylene blue, eosin and azure B. The stain 
was prepared by dissolving 3.8g of Giemsa powder in 250 ml methanol, the 
solution was heated to 60°C and then slowly 250 ml glycerin was added and the 
solution was filtered and allowed to stand. 
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2.2.4.4.2 Preparation of Giemsa stain working solution  
Working solution was prepared by adding 90 ml distilled water to 10 ml stock 
solution.  
2.2.4.5 In vitro macrophage cell line culture 
Human   macrophage (THP1) cell line  were cultured in sterile DMEM complete 
media in disposable tissue culture flasks Under sterile condition the contents of 
the thawed culture tube was transferred into 15 ml sterile falcon tube and 2mL of 
complete media was added to wash the cells from dimethylsulphoxide (DMSO) or 
glycerol in the freezing media. The cells were centrifuged at 1200 rpm for 10 
minutes at 4°c. The supernatant was discarded and 1mL of complete media was 
added to the pellets and mixed well. The cells were transferred into 50 mL sterile 
tissue culture flask and about 10-15 ml of complete media was added and 
incubated in 5% CO2 atmosphere at 37°c. The cells were examined under the 
inverted microscope every day to detect growth and contamination.  
2.2.4.6 Cell freezing  
Well growing macrophage culture was centrifuged at 1300 rpm for 10 minutes. 
The supernatant was discarded and the pellets were resuspended in 0.5 ml 
complete media. 300 µl was taken into cryovial tube and the volume was 
completed to 1 ml using the freezing media. Tubes were stored in -80°C 
refrigerator as stock.                                                                                                                                                          
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2.2.4.7 In vitro infection of the macrophage with the leishmania parasite 
Cultures of the stationary growth phase of the parasite were transferred into 15 ml 
sterile falcon tubes and centrifuged at 1200 rpm for 10 minutes; the pellets were 
resuspended in 1 ml complete media. 10 µL was taken and mixed with 90 µL of 
formalin 2%. 5 µL of the mixture was used for counting of the promastigotes 
using haemocytometer.  
Cultures of well grown macrophages were transferred into 15 ml falcon tube and 
centrifuged at 1200 rpm for 10 minutes; the pellets were resuspended in 1 ml 
complete media. 10 µL was added to 90µL of trypan blue 0.4% for counting of 
live macrophages using haemocytometer. The growing THP1 cells were infected 
by stationary phase promastigotes of L. donovani and L.major   at ratio 1:5 in 
sterile tissue culture plates. The infected culture was incubated in 5% CO2 
atmosphere at 37°c. The drug was added 3 days post infection. 
2.2.4.8 Measurement of the parasite inhibition and drug assay   
2.2.4.8.1 Preparations of the drugs 
Isoniazid: 
Isoniazid was obtained from Sigma Aldrich (Germany) as standard powder of 
known potency. Five (5) mg of powder was dissolved in 5mL distilled water to 
produce a solution of 1 mg/ml (1µg/µl) concentration. The solution was filtered 
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using a membrane filter of 0.22 porosity. Doses of volume equivalent to 0.1, 0.2 
and 0.4 µg/ml were prepared using sterile water for injection. 
Sulfadoxine and pyrimethamine combination:  
The combination was obtained as tablets from Efroze chemical industries 
(Pakistan). 2 tablets were ground, dissolved in sterile water for injection and 
filtered by using a membrane filter of 0.22 porosity. Doses of volume equivalent 
to 1.9, 2.9, 3.8 µg/ml pyrimethamine and 38.1, 57.1, 76.2 µg/ml sulphadoxine was 
prepared. 
Sodium stibogluconate 
It was provided as intravenous solution equivalent to 100 mg/ml pentavalent 
antimony from Albert David LTD (India). Serial dilutions were made to prepare 
doses of 20µg/ml for L. major and 24µg/ml for L. donovani.    
Liposomal amphotericin B 
Ambisome was provided as 50 mg powder for concentrate for IV infusion from 
Gilead sciences LTD (Ireland). Serial dilutions were made to prepare dose of 
10µg/ml for L. major and L. donovani.    
2.2.4.8.2 The effect on the promastigotes 
Growth inhibition of different drug concentrations was determined by comparing 
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the activity of treated promastigotes culture with untreated and SSG treated 
cultures. This was done by examining the cultures under the inverted microscope 
after 1, 2, 3, 24, 48 and 72 hrs.  
 2.2.4.8.3 The effect on the amastigotes                                                                                                                                                                                
Three days post addition of the drug the treated and untreated macrophage 
infected cultures were centrifuged at 12000 rpm for 10 minutes, the supernatant 
was discarded and the pellets were resuspended in 1ml complete media, then 
smears were prepared and examined under the microscope. Percentage of killing 
for each drug was calculated.  
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2.2.4.8.4 Isoniazid (INH) experiments 
The effect on the promastigotes  
L.major promastigotes: 1000 µl of growing L.major culture was added into 15 
well of 24 wells tissue culture plate. The drug was added at 0.1, 0.2 and 0.4 µg/ml 
in triplicate wells. Promastigote culture without Isonaizid and Promastigote 
culture with 20µg/ml SSG were added in triplicate wells and used as controls.                     
L.donovani promastigotes: 1000 µl of well growing L.donovani culture was 
added into 15 well of 24 wells tissue culture plate. The drug was added at 0.1, 0.2 
and 0.4 µg/ml in triplicate wells. Promastigote culture without Isonaizid and 
Promastigote culture with 24µg/ml SSG were added in triplicate wells and used as 
controls.                     
The effect on the amastigotes 
L.major amastigotes: 1000 µl of L. major infected macrophage culture was 
added into 15 well of 24 wells tissue culture plate. The drug was added at 0.1, 0.2 
and 0.4 µg/ml in triplicate wells. Infected macrophages without Isonaizid and 
infected macrophages with 20µg/ml SSG were added in triplicate wells and used 
as controls.                    
L.donovani amastigotes: 1000 µl of L.donovani infected macrophage culture was 
added into 15 well of 24 wells tissue culture plate. The drug was added at 0.1, 0.2 
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and 0.4 µg/ml in triplicate wells. Infected macrophages without Isonaizid and 
infected macrophages with 24µg/ml SSG were added in triplicate wells and used 
as controls.                                                            
2.2.4.8.5 Combination of INH and SSG experiments 
The effect on the promastigotes  
L.major promastigotes: 1000 µl of growing L.major culture was added into 24 
well of 24 wells tissue culture plate. The drugs were added at 0.1, 0.2 and 0.4 
µg/ml of INH and 0.1, 0.2 and 0.4 each with 20 µg/ml SSG in triplicate wells. 
Promastigote culture without the drugs and promastigote culture with 20µg/ml 
SSG were added in triplicate wells and used as controls.                     
L. donovani promastigotes: 1000 µl of growing L.donovani culture was added 
into 24 well of 24 wells tissue culture plate. The drugs were added at 0.1, 0.2 and 
0.4 µg/ml of INH and 0.1, 0.2 and 0.4 each with 24 µg/ml SSG in triplicate wells. 
Promastigote culture without the drugs and promastigote culture with 24µg/ml 
SSG were added in triplicate wells and used as controls.                                           
The effect on the amastigotes 
L.major amastigotes: 1000 µl of L. major infected macrophage culture was 
added into 24 well of 24 wells tissue culture plate. The drug was added at 0.1, 0.2 
and 0.4 µg/ml of INH and 0.1, 0.2 and 0.4 each with 20 µg/ml SSG in triplicate 
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wells. Infected macrophages without the drugs and infected macrophages with 
20µg/ml SSG were added in triplicate wells and used as controls.                    
L.donovani amastigotes: 1000 µl of L.donovani infected macrophage culture was 
added into 24 well of 24 wells tissue culture plate. The drug was added at 0.1, 0.2 
and 0.4 µg/ml of INH and 0.1, 0.2 and 0.4 each with 24 µg/ml SSG in triplicate 
wells. Infected macrophages without the drugs and infected macrophages with 
24µg/ml SSG were added in triplicate wells and used as controls.                                         
2.2.4.8.6 Combination of INH and ambisome experiment 
The effect on the promastigotes  
  L.major promastigotes: 1000 µl of growing L.major culture was added into 24 
well of 24 wells tissue culture plate. The drugs were added at 0.1, 0.2 and 0.4 
µg/ml of INH and 0.1, 0.2 and 0.4 each with 10 µg/ml amBisome in triplicate 
wells. Promastigote culture without the drugs and Promastigote culture with 
10µg/ml amBisome were added in triplicate wells and used as controls.                                                     
L.donovani promastigotes: 1000 µl of growing L.donovani culture was added 
into 24 well of 24 wells tissue culture plate. The drugs were added at 0.1, 0.2 and 
0.4 µg/ml of INH and 0.1, 0.2 and 0.4 each with 10µg/ml amBisome in triplicate 
wells. Promastigote culture without the drugs and Promastigote culture with 
10µg/ml amBisome were added in triplicate wells and used as controls.                                                             
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The effect on the amastigotes 
L.major amastigotes: 1000 µl of L. major infected macrophage culture was 
added into 24 well of 24 wells tissue culture plate. The drug was added at 0.1, 0.2 
and 0.4 µg/ml of INH and 0.1, 0.2 and 0.4 each with 10µg/ml amBisome in 
triplicate wells. Infected macrophages without the drugs and infected 
macrophages with 10µg/ml amBisome were added in triplicate wells and used as 
controls.    
 L.donovani amastigotes: 1000 µl of L.donovani infected macrophage culture 
was added into 24 well of 24 wells tissue culture plate. The drug was added at 0.1, 
0.2 and 0.4 µg/ml of INH and 0.1, 0.2 and 0.4 each with 10µg/ml amBisome in 
triplicate wells. Infected macrophages without the drugs and infected 
macrophages with 10µg/ml amBisome were used as controls.  
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2.2.4.8.7 Combination of sulfadoxine and pyrimethamine experiment 
 Table (1): Concentration of sulphadoxine ? pyrimethamine Combination. 
 Concentration (µg/ml) 
    1 1.9 pyrimethamine and 38.1 sulfadoxine 
    2 2.9  pyrimethamine and 57.1sulfadoxine 
    3 3.8 pyrimethamine and 76.2sulfadoxine 
 
The effect on the promastigotes  
 L.major promastigotes: 1000 µl of growing L.major culture was added into 15 
well of 24 wells tissue culture plate. The drug was added at the three different 
concentrations in triplicate wells. Promastigote culture without the drug and 
promastigote culture with 20µg/ml SSG were added in triplicate wells and used as 
controls.                                                     
L.donovani promastigotes: 1000 µl of growing L.donovani culture was added 
into 15 well of 24 wells tissue culture plate. The drug was added at the three 
different concentrations in triplicate wells. Promastigote culture without the drug 
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and promastigote culture with 24µg/ml SSG were added in triplicate wells and 
used as controls.                                                     
The effect on the amastigotes 
L.major amastigotes: 1000 µl of L. major infected macrophage culture was 
added into 15 well of 24 wells tissue culture plate. The drug was added at the 
three different concentrations in triplicate wells. Infected macrophages without 
the drug and infected macrophages with 20µg/ml SSG were added in triplicate 
wells and used as controls.                                                
L.donovani amastigotes: 1000 µl of L.donovani infected macrophage culture was 
added into 15 well of 24 wells tissue culture plate. The drug was added at the 
three different concentrations in triplicate wells. Infected macrophages without 
the drug and infected macrophages with 24µg/ml SSG were added in triplicate 
wells and used as controls.                                                
2.2.4.9 Preparation of Geimsa stained smears 
30 µL of the infected culture was taken; air dried and fixed with 70% methanol 
and stained with 10% Geimsa stain for 10 minutes and rinsed with tap water, then 
examined under the microscope.  
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2.2.5 Statistical analysis 
The results were statistically analyzed using paired sample student t test taking 
0.05 as level of significance. 
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3.1 Alignment of the pathogen target sequence and leishmania sequence 
3.1.1 Alignment of leishmania major 3-oxoacyl- acyl carrier protein 
synthaseII and mycobacterium fatty acid synthase  
Query: 3-oxoacyl-acyl carrier protein synthase ii; beta-ketoacyl synthase family 
protein (Leishmania major >gi|68129107|emb|CAJ06755.1| putative beta-ketoacyl  
synthase family protein (Leishmania major strain Friedlin)  
Subject: fatty acid synthase (Mycobacterium tuberculosis H37Rv) 
>gi|148662361|ref|YP_001283884.1 
Table (2): Alignment score of isoniazid target sequence in L.major and M. 
tuberculosis.       
Max score  Total score Query coverage E value 
55.5 134 64% 3e? 11 
               
Dot matrix view 
Plot of leishmania major protein sequence vs mycobacterium protein 
sequence 
This dot matrix view shows regions of similarity based upon the BLAST results. 
The query sequence is represented on the X-axis and the subject is represented on 
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the Y-axis. The numbers represent the bases/residues of the subject. Alignments 
are shown in the plot as lines. Figure (9). 
3.1.2 Alignment of leishmania donovani 3-oxoacyl- acyl carrier protein 
synthaseII and mycobacterium fatty acid synthase  
Query: unnamed protein product (Leishmania donovani BPK282A1) 
gi|322502344|emb|CBZ37428.1|.  
Subject: fatty acid synthase (Mycobacterium tuberculosis H37Rv) 
>gi|148662361|ref|YP_001283884.1 
Table (3): Alignment score of Isoniazid target sequence in L.donovani   and M. 
tuberculosis 
Max score Total score Query coverage E value 
54.7 132 57% 5e? 11 
               
 Dot matrix view 
Plot of leishmania donovani protein sequence vs mycobacterium protein 
sequence 
This dot matrix view shows regions of similarity based upon the BLAST results. 
The query sequence is represented on the X-axis and the numbers represent the 
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bases/residues of the query. The subject is represented on the Y-axis and again the 
numbers represent the bases/residues of the subject. Alignments are shown in the 
plot as lines. Figure (10). 
3.1.3 Alignment of dihydrofolate reductase-thymidylate synthase 
(Leishmania major) and dihydrofolate reductase-thymidylate synthase 
(Plasmodium falciparum) 
Query: dihydrofolate reductase-thymidylate synthase (Leishmania major) 
>gi|118936|sp|P07382.1|. 
Subject: dihydrofolate reductase-thymidylate synthase (Plasmodium falciparum) 
>gi|623444|gb|AAB59212.1|. 
Table (4): Alignment score of pyrimethamine? sulfadoxine target sequence in 
L.major and P. falciparum. 
Max score Total score Query coverage E value 
341 454 91% 4e? 98 
                 
Dot matrix view 
Plot of leishmania protein sequence vs. plasmodium sequence   
This dot matrix view shows regions of similarity based upon the BLAST results.  
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The query sequence is represented on the X-axis and the numbers represent the 
bases/residues of the query. The subject is represented on the Y-axis and again the 
numbers represent the bases/residues of the subject. Alignments are shown in the 
plot as lines. Figure (11). 
3.1.4 Alignment of dihydrofolate reductase-thymidylate synthase 
(Leishmania major) and dihydrofolate reductase-thymidylate synthase 
(Plasmodium vivax) 
Query: dihydrofolate reductase-thymidylate synthase (Leishmania major) 
>gi|118936|sp|P07382.1|. 
Subject: dihydrofolate reductase (Plasmodium vivax) 
gi|3550616|emb|CAA05916.1|.  
Table (5): Alignment score of pyrimethamine? sulfadoxine target sequence in 
L.major and P. vivax 
Max score Total score Query coverage E value 
65.1 65.1 30% 2e? 15 
 
Dot matrix view 
Plot of leishmania protein sequence vs. plasmodium sequence      
This dot matrix view shows regions of similarity based upon the BLAST results.  
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The query sequence is represented on the X-axis and the numbers represent the 
bases/residues of the query. The subject is represented on the Y-axis and again the 
numbers represent the bases/residues of the subject. Alignments are shown in the 
plot as lines. Figure (12). 
3.1.5 Alignment of dihydrofolate reductase-thymidylate synthase 
(Leishmania donovani) and dihydrofolate reductase-thymidylate synthase 
(Plasmodium falciparum) 
Query:   dihydrofolate reductase-thymidylate synthase (Leishmania donovani) 
gi|322496602|emb|CBZ31672.1|  
Subject:  dihydrofolate reductase-thymidylate synthase (Plasmodium falciparum) 
gi|623444|gb|AAB59212.1|  
Table (6): Alignment score of pyrimethamine? sulfadoxine target sequence in 
L.donovani and P. falciparum. 
Max score Total score Query coverage E value 
340 452 91% 1e? 97 
 
Dot matrix view 
Plot of leishmania protein sequence vs. plasmodium sequence     
This dot matrix view shows regions of similarity based upon the BLAST results.      
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The query sequence is represented on the X-axis and the numbers represent the 
bases/residues of the query. The subject is represented on the Y-axis and again the 
numbers represent the bases/residues of the subject. Alignments are shown in the 
plot as lines. Figure (13). 
3.1.6 Alignment of dihydrofolate reductase-thymidylate synthase 
(Leishmania donovani) and dihydrofolate reductase-thymidylate synthase 
(Plasmodium vivax) 
Query:   dihydrofolate reductase-thymidylate synthase [Leishmania donovani] 
gi|322496602|emb|CBZ31672.1|  
Subject: dihydrofolate reductase-thymidylate synthase [Plasmodium vivax] 
gi|99082919|gb|ABF66633.1|  
Table (7): Alignment score of pyrimethamine? sulfadoxine target sequence in 
L.donovani and P. vivax. 
Max score Total score Query coverage E value 
332 399 85% 3e? 95 
            
Dot matrix view 
Plot of leishmania protein sequence vs. plasmodium sequence  
This dot matrix view shows regions of similarity based upon the BLAST results.  
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The query sequence is represented on the X-axis and the numbers represent the 
bases/residues of the query. The subject is represented on the Y-axis and again the 
numbers represent the bases/residues of the subject. Alignments are shown in the 
plot as lines. Figure (14). 
 
 
 
 
 
 
 
 
 
 
 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
 ϰϵ 
 
 
 
 
 
Figure (3): Alignment score of isoniazid target sequence in L.major and M. 
tuberculosis. 
 
 
 
 
 
 
Figure (4):  Alignment score of Isoniazid target sequence in L.donovani   and M. 
tuberculosis. 
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Figure (5): Alignment score of pyrimethamine? sulfadoxine target sequence in 
L.major and P. falciparum. 
 
 
     
 
 
 
Figure (6): Alignment score of pyrimethamine? sulfadoxine target sequence in 
L.major and P. vivax. 
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Figure (7): Alignment score of pyrimethamine? sulfadoxine target sequence in 
L.donovani and P. falciparum.  
 
 
 
 
  
 
 
Figure (8): Alignment score of pyrimethamine? sulfadoxine target sequence in 
L.donovani and P. vivax. 
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Fig (9): Dot matrix view of blasting 3-oxoacyl-acyl carrier protein synthase ii 
(Leishmania major strain Friedlin) and fatty acid synthase (Mycobacterium 
tuberculosis H37Rv]).   
 
 
           
Fig (10): Dot matrix view of blasting unnamed protein product (Leishmania 
donovani) and Fatty acid synthase (Mycobacterium tuberculosis H37Rv). 
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Fig (11): Dot matrix view of blasting dihydrofolate reductase-thymidylate synthase 
 (Leishmania major) and dihydrofolate reductase-thymidylate synthase (Plasmodium  
falciparum). 
 
  
Fig (12): Dot matrix view of blasting dihydrofolate reductase-thymidylate 
synthase (Leishmania major) and dihydrofolate reductase-thymidylate synthase 
(Plasmodium vivax). 
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Fig (13): Dot matrix view of blasting dihydrofolate reductase-thymidylate 
synthase (Leishmania donovani) and dihydrofolate reductase-thymidylate 
synthase (Plasmodium falciparum). 
 
    
Fig (14): Dot matrix view of blasting dihydrofolate reductase-thymidylate 
synthase (Leishmania donovani) and dihydrofolate reductase-thymidylate 
synthase(Plasmodium vivax). 
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3.2 Evaluation of the antileishmanial activity of the candidate drugs on 
leishmania using THP1 macrophage cell line  
3.2.1 Parasite isolates and culture 
The growth of leishmania parasite promastigotes was achieved in both NNN and 
CM. figures (32 and 33). 
3.2.2 Molecular characterization of the isolate 
Kinetoplast DNA (KDNA-PCR)  
Based on the size of the DNA amplified band, L.donovani complex showed an 
amplicon of 800 bp, and L. major showed an amplicon of 700 bp figure (15). 
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Fig (15): Stained agarose gel electrophoresis of PCR amplified kDNA of 
leishmania. Lane 1, 2: L.major, lane 3, 4: L.donovani, lane 5: positive control 
L.donovani, lane 6: positive control L.major, lane7: negative control. 
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3.2.3 Measurement of the parasite inhibition and drug assay   
3.2.3.1 The effect on the promastigotes 
1- INH 
There was no detectable effect in the activity in all wells of L.major and 
L.donovani after 1, 2 and 3 hrs. But after 24 hrs, there was a lot of clusters with 
round shape formation as compared to SSG treated and negative control. After 
48 hrs almost 90% of the promastigotes have transformed to round shaped. 
After 72 hrs no change was observed. 
2- INH plus  SSG 
 The results were similar to that of INH alone 
3- INH  plus amBisome 
There was no detectable effect in the activity in all wells of L.major and 
L.donovani after 1and 2hrs. However after 3 hrs, there was marked reduction in 
the activity, and a complete reduction of the activity was detected after 24 hrs and 
48 hrs compared with the negative control. 
4- Sulphadoxine- pyrimethamine combination 
There was no reduction in the activity in all wells of L.major and L.donovani 
after 1, 2 and 3 hrs. After 24 hrs of incubation, a change in the shape, activity 
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and clustering of the parasites was detected in the treatment wells compared with 
SSG and the negative controls. After 48 and 72 hrs there was marked activity 
reduction. 
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3.2.3.2 The effect on the amastigotes    
3.2.3.2.1 Antileishmanial activity of isoniazid against L.donovani using in 
vitro macrophage infection assay 
To evaluate the antileishmanial activity of INH against leishmania donovani 
amastigotes, the following concentrations of INH were added to macrophage 
infected cells, 0.1, 0.2 and 0.4µ g/ml. The results showed   a decrease in the mean 
number of amastigotes per 100 THP1 as compared to the untreated cells (negative 
control) and increase in the percentage of killing as shown in figure (16 and 17). 
Table (8): Mean number of leishmania donovani amastigotes per 100 THP1 and 
percentage of killing produced by 0.1, 0.2 and 0.4 µ g/ml of isoniazid and 24 
µ g/ml of SSG.  
                               Concentration Negative 
control 
0.1 0.2 0.4 24 SSG 
Mean No of   amastigotes 
Per 100THP1 + SEM 
374* +8.5 362* +10.7 332* +8.5 277* +22.5  792 +13.2 
% of killing 52.8% 54.3% 58.8% 65% – 
 
Note: * indicates significance level less than 0.05 (P < 0.05). 
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Fig (16):  Mean number Leishmania donovani amastigotes   per 100 THP1 in   
          the presence of isoniazid using in vitro THP1 infection assay. 
 
 
 
 Fig (17): Percentage of killing of Leishmania donovani  amastigotes in  
               the presence of isoniazid using in vitro THP1 infection assay.     
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3.2.3.2.2 Antileishmanial activity of isoniazid against L.major using in vitro 
macrophage infection assay 
To evaluate the antileishmanial activity of INH against leishmania major 
amastigotes, the following concentrations of INH were added to macrophage 
infected cells, 0.1, 0.2 and 0.4µ g/ml. The results showed   a decrease in the mean 
number of amastigotes per 100 THP1 as compared to the untreated cells (negative 
control) and increase in the percentage of killing as shown in figure (18 and 19). 
Table (9): Mean number of leishmania major amastigotes per 100 THP1 and 
percentage of killing produced by 0.1, 0.2 and 0.4 µ g/ml of isoniazid and 20 
µ g/ml of SSG. 
                               Concentration Negative 
control 
0.1 0.2 0.4 20 SSG 
Mean No of   amastigotes 
Per 100THP1 +SEM 
542*+47.1 459*+48.3 313*+21.4 333*+10.7  785+38.7 
% of killing 31% 41.5% 60.2% 57.6% – 
 
Note: * indicates significance level less than 0.05 (P < 0.05). 
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Fig (18):  Mean number Leishmania major amastigotes per 100 THP1  
      in the presence of isoniazid using in vitro THP1 infection assay. 
 
 
 
Fig (19): Percentage of killing of Leishmania major   amastigotes  
in the presence of isoniazid using in vitro THP1 infection assay. 
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3.2.3.2.3 Antileishmanial activity of isoniazid plus SSG against L.donovani 
using in vitro macrophage infection assay 
To evaluate the antileishmanial activity of INH plus SSG against leishmania 
donovani amastigotes, the following concentrations of INH were added to 
macrophage infected cells, 0.1, 0.2 and 0.4µ g/ml each plus 24µ g/ml SSG. The 
results showed   a decrease in the mean number of amastigotes per 100 THP1 and 
increase in the percentage of killing compared to INH alone treated cells as shown 
in figure (20 and 21). 
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Table (10):  Mean number of leishmania donovani amastigotes per 100 THP1 
and percentage of killing produced by 0.1, 0.2 and 0.4 µ g/ml of isoniazid alone 
and 0.1, 0.2 and 0.4µ g/ml each plus 24µ g/ml SSG and 24µ g/ml SSG alone.  
Concentration Mean No of   amastigotes 
Per 100THP1+ SEM 
% of killing 
0.1 213*+6.1 50.7% 
0.2 219*+7.0 53.3% 
0.4 201*+5.1 57.1% 
0.1+  24  SSG 184*+3.6 60.8% 
0.2+  24   SSG 143*+3.5 69.5% 
0.4+   24  SSG 130*+5.6 72.3% 
SSG 171*+5.1 63.5% 
–Ve 469+17.1  
 
Note: * indicates significance level less than 0.05 (P < 0.05). 
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Fig (20):  Mean number of Leishmania donovani amastigotes per 100 THP1 in  
         the presence of isoniazid plus SSG using in vitro THP1 infection assay. 
 
 
 
Fig (21): Percentage of killing of Leishmania donovani   amastigotes in the      
presence of isoniazid plus SSG using in vitro THP1 infection assay.      
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3.2.3.2.4 Antileishmanial activity of isoniazid plus SSG against L.major using 
in vitro macrophage infection assay 
To evaluate the antileishmanial activity of INH plus SSG against leishmania 
major amastigotes, the following concentrations of INH were added to 
macrophage infected cells, 0.1, 0.2 and 0.4µ g/ml each plus 20µ g/ml SSG. The 
results showed   a decrease in the mean number of amastigotes per 100 THP1 and 
increase in the percentage of killing compared to INH alone treated cells as shown 
in figure (22 and 23). 
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Table (11): Mean number of leishmania major amastigotes per 100 THP1 and 
percentage of killing produced by 0.1, 0.2 and 0.4 µ g/ml of isoniazid alone and 
0.1, 0.2 and 0.4µ g/ml each plus 20µ g/ml SSG and 20 µ g/ml SSG alone.  
Concentration Mean No of amastigotes Per 
100THP1+ SEM 
% of killing 
0.1 260*+6.3 34.7% 
0.2 220*+10.1 42.4% 
0.4 153*+8.1 61.2% 
0.1+  20  SSG 107*+9.5 72.8% 
0.2+  20   SSG 88*+9.2 77.7% 
0.4+   20  SSG 64*+6.5 83.8% 
 20 SSG 128*+9.2 67.5% 
–Ve 394+8.7  
 
Note: * indicates significance level less than 0.05 (P < 0.05). 
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Fig (22): Mean number of Leishmania major amastigotes per 100 THP1 in the 
presence of isoniazid plus SSG using in vitro THP1 infection assay. 
 
 
Fig (23): Percentage of killing of Leishmania major   amastigotes in the presence 
of isoniazid plus SSG using in vitro THP1 infection assay.       
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3.2.3.2.5 Antileishmanial activity of isoniazid plus amBisome against 
L.donovani using in vitro macrophage infection assay 
To evaluate the antileishmanial activity of INH plus amBisome against 
leishmania donovani amastigotes, the following concentrations of INH were 
added to macrophage infected cells, 0.1, 0.2 and 0.4µ g/ml each plus 10µ g/ml 
amBisome. The results showed   a decrease in the mean number of amastigotes 
per 100 THP1 and increase in the percentage of killing compared to INH alone 
treated cells as shown in figure (24 and 25). 
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Table (12): Mean number of leishmania donovani amastigotes per 100 THP1 and 
percentage of killing produced by 0.1, 0.2 and 0.4µ g/ml of isoniazid alone and 
0.1, 0.2 and 0.4µ g/ml each plus 10µ g/ml amBisome and 10µ g/ml amBisome 
alone. 
Concentration Mean No of   amastigotes 
Per 100THP1+ SEM 
% of killing 
0.1 193* + 4.0 48% 
0.2 178* +5.2 52% 
0.4 166* +3.8 55.3% 
0.1+10amb 119* +5.5 67.9% 
0.2+ 10amb 110 *+8.1 70.4% 
0.4+10amb 92*  +4.7 75.2% 
10 amb 153* +4.2  58.8% 
–Ve 371 +6.2  
  
         Note: * indicates significance level less than 0.05 (P < 0.05). 
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Fig (24): Mean number of Leishmania donovani amastigotes per 100 THP1 in the 
         presence of isoniazid plus amBisome using in vitro THP1 infection assay. 
 
 
 
Fig (25): Percentage of killing of Leishmania donovani   amastigotes in the 
presence of isoniazid plus amBisome using in vitro THP1 infection assay. 
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3.2.3.2.6 Antileishmanial activity of isoniazid plus amBisome against L.major 
using in vitro macrophage infection assay 
To evaluate the antileishmanial activity of INH plus amBisome against 
leishmania major amastigotes, the following concentrations of INH were added to 
macrophage infected cells, 0.1, 0.2 and 0.4µ g/ml each plus 10µ g/ml amBisome. 
The results showed   a decrease in the mean number of amastigotes per 100 THP1 
and increase in the percentage of killing compared to INH alone treated cells as 
shown in figure (26 and 27). 
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Table (13): Mean number of leishmania major amastigotes per 100 THP1 and 
percentage of killing produced by 0.1, 0.2 and 0.4µ g/ml of isoniazid alone and 
0.1, 0.2 and 0.4µ g/ml each plus 10µ g/ml amBisome and 10µ g/ml amBisome 
alone. 
Concentration Mean No of  amastigotes Per 
100THP1+ SEM 
% of killing 
0.1 228*+8.2 30.3% 
0.2 201*+11.8 38.5% 
0.4 17*9+9.2 45.3% 
0.1+10amb 115*+8.1 64.8% 
0.2+ 10amb 96*+9.3 70.6% 
0.4+10amb 75*+11.2 77.1% 
10 amb 162*+6.2 50.5% 
–Ve 327+11.1  
 
 Note: * indicates significance level less than 0.05 (P < 0.05). 
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Fig (26): Mean number of Leishmania major amastigotes per 100 THP1 in the 
presence of isoniazid plus amBisome using in vitro THP1 infection assay. 
 
 
Fig (27): Percentage of killing of Leishmania major amastigotes in the presence 
of isoniazid plus amBisome using in vitro THP1 infection assay. 
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3.2.3.2.7 Antileishmanial activity of Sulphadoxine plus pyrimethamine 
against L.donovani using in vitro macrophage infection assay 
To evaluate the antileishmanial activity of Sulphadoxine plus pyrimethamine 
against leishmania donovani amastigotes, the following concentrations were 
added to macrophage infected cells, 1.9 pyrimethamine and 38.1 sulfadoxine, 2.9 
pyrimethamine and 57.1 sulfadoxine and 3.8 pyrimethamine and 76.2sulfadoxine 
The results showed   a decrease in the mean number of amastigotes per 100 THP1 
as compared to the untreated cells (negative control) and increase in the 
percentage of killing as shown in figure (28 and 29). 
 
 
 
 
 
 
 
 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
 ϳϲ 
 
 
Table (14): Mean number of leishmania donovani amastigotes per 100 THP1 and 
percentage of killing produced by different concentrations of Sulphadoxine plus 
pyrimethamine and 24µ g/ml of SSG. 
Concentration Mean No of   amastigotes 
Per 100THP1+ SEM 
% of killing 
  1 373*+7.2 27.6% 
  2 350*+5.7 32% 
 3 317*+7.8 38.5% 
 24 SSG 212*+10.4 58.8% 
 –Ve 515+14.5  
 
Note: * indicates significance level less than 0.05 (P < 0.05). 
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Fig (28): Mean number of Leishmania donovani amastigotes per 100 THP1 in the 
presence of sulfadoxine plus pyrimethamine using in vitro THP1 infection assay. 
 
 
Fig (29): Percentage of killing of Leishmania donovani amastigotes in the 
presence of sulfadoxine plus pyrimethamine using in vitro THP1 infection assay.  
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3.2.3.2.8 Antileishmanial activity of Sulphadoxine plus pyrimethamine 
against L.major using inviro macrophage infection 
To evaluate the antileishmanial activity of Sulphadoxine plus pyrimethamine 
against leishmania majori amastigotes, the following concentrations were added 
to macrophage infected cells, 1.9 pyrimethamine and 38.1 sulfadoxine, 2.9 
pyrimethamine and 57.1 sulfadoxine and 3.8 pyrimethamine and 76.2sulfadoxine 
The results showed   a decrease in the mean number of amastigotes per 100 THP1 
as compared to the untreated cells (negative control) and increase in the 
percentage of killing as shown in figure (30 and 31). 
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Table (15): Mean number of leishmania major amastigotes per 100 THP1 and 
percentage of killing produced by different concentrations of Sulphadoxine plus 
pyrimethamine and 24µ g/ml of SSG. 
Concentration Mean No of   amastigotes 
Per 100THP1+ SEM 
% of killing 
   1 342*+4.7 28.9% 
   2 308*+5.9 35.9% 
   3 286*+7.0 40.9% 
20  SSG 189*+6.0 60.7% 
 –Ve 481+9.2  
 
Note: * indicates significance level less than 0.05 (P < 0.05). 
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Fig (30): Mean number of Leishmania major amastigotes per 100 THP1 in the 
presence of sulfadoxine plus pyrimethamine using in vitro THP1 infection assay. 
 
 
Fig (31): Percentage of killing of Leishmania major amastigotes in the presence 
of sulfadoxine plus pyrimethamine using in vitro THP infection assay.  
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Statistics  
Paired Sample Test 
L.donovani L.major 
Negative Vs S.D S.E Tvalue sig Negative Vs S.D S.E Tvalue sig 
0.1 INH 22.1 12.8 -32.7 .001 0.1 INH 39.9 23.1 -10.5 .009 
0.2 INH 30.1 17.3 -24.9 .002 0.2 INH 62.3 36.0 -9.1 .012 
0.4 INH 17.6 10.1 -45.3 .000 0.4 INH 77.7 44.9 -9.8 .010 
0.1 INH + SSG 26.8 15.5 -18.4 .003 0.1 INH  + SSG 8.5 4.9 -58.2 .000 
0.2 INH + SSG 35.3 20.4 -16.0 .004 0.2 INH + SSG 30.0 17.3 -16.7 .004 
0.4 INH + SSG 26.1 15.0 -22.5 .002 0.4 INH + SSG 4.0 2.3 -142.9 .000 
0.1 INH  + amB 31.0 17.9 -11.8 .007 0.1 INH  + amB 20.2 11.7 -21.6 .002 
0.2 INH  + amB 16.5 9.5 -24.3 .002 0.2 INH  + amB 24.2 14.0 -18.6 .003 
0.4 INH + amB 37.4 21.6 -11.7 .007 0.4 INH + amB 3.6 2.1 -134.0 .000 
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L.donovani L.major 
SSG  Vs S.D S.E Tvalue sig SSG  Vs S.D S.E Tvalue sig 
0.1 INH 34.0 19.6 4.9 .039 0.1 INH 64.2 37.1 11.9 .007 
0.2 INH 26.2 15.1 5.6 .030 0.2 INH 87.1 50.2 7.8 .016 
0.4 INH 38.6 22.3 2.4 .133 0.4 INH 52.4 30.2 -4.7 .042 
0.1 INH + SSG 3.6 2.1 1.7 .228 0.1 INH  + SSG 31.2 18.0 -1.2 .364 
0.2 INH + SSG 19.5 11.2 -13.5 .005 0.2 INH + SSG 9.5 5.5 -4.2 .050 
0.4 INH + SSG 17.4 10.1 -4.4 .048 0.4 INH + SSG 27.2 15.7 -4.1 .053 
 
 
L.donovani L.major 
amBisome  Vs S.D S.E Tvalue sig amBisom  Vs S.D S.E Tvalue sig 
0.1 INH  + amB 3.6 2.1 -22.5 .002 0.1 INH  + amB 6.2 3.6 -9.4 .011 
0.2 INH  + amB 19.4 11.2 -5.9 .028 0.2 INH  + amB 11.1 6.4 -6.7 .022 
0.4 INH + amB 17.4 10.1 -8.6 .013 0.4 INH + amB 15.1 8.7 -7.0 .020 
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                Fig (32): Culture of  L.major promastigotes in DMEM complete media,    
               Geimsa stain X100 
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                Fig (33): Culture of L.donovani promastigotes in DMEM complete  
                media, Geimsa stain X100 
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 Fig (34):  Infection of macrophages human cell line THP1 with L.major    
promastigotes, 3days post infection. Geimsa stainX100 
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 Fig (35):  Infection of macrophages human cell line THP1 with Ldonovani 
promastigotes, 3post infection. Geimsa stainX100 
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Leishmaniasis is a major public health problem in Sudan and different clinical 
forms are endemic in many areas of the country (Zijlstra and El Hassan, 2001). It 
is difficult to treat and there is increasing resistance developing against the 
currently available drugs (Davidson, 1999). Sodium stibogluconate (SSG) is the 
first line of treatment of visceral leishmaniasis in Sudan. Liposomal amphotericin 
B is the second line treatment. Currently combination of sodium stibogluconate 
and liposomal amphotericin B is under trial. 
In this study the tested Leishmania isolates were cultured from the parasite cryo 
bank in the institute of endemic diseases and previously typed by multienzyme 
electrophoresis. The two isolates were characterized in this study by KDNA PCR 
amplification. The result showed an amplicon of 800 bp of L. donovani complex 
and an amplicon of 700 bp of L. major complex as previously reported by Smyth 
et al (1992). The in vitro culture of the promastigotes of the two species was 
achieved in both the triple N and DMEM media.  
In vitro infection of human macrophage THP1 is a widely used method for in 
vitro evaluation of new anti leishmanial drugs and for testing the drug sensitivity 
of the parasite. A significant parasite infection by L. donovani and L. major 
promastigotes was achieved in this study. 
The completion of the sequencing of the whole genome and the analysis of the 
proteomes of leishmania, mycobacteria and plasmodium opens access to valuable 
data that can be used for diagnostics, drugs and vaccine discovery. The aim of this 
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study was to identify new drug targets for production of safe, effective and 
affordable drugs using comparative bioinformatics and to determine the 
sensitivity of the selected drugs against leishmania using in vitro drug sensitivity 
assay. Leishmaina and mycobacteria belong to different phyla, the former is a 
protozoan of the family trypansomatidae and the latter is a bacteria belonging to 
Mycobacteriacae, while plasmodium belongs to the family plasmodiidae.  
Interestingly alignment of mycobacterium fatty acid synthase and leishmania 
major and leishmania donovani 3-oxoacyl- acyl carrier protein synthaseII showed 
50% maximum identities.  The mycobacterium fatty acid synthase enzyme that is 
responsible for formation of mycolic acid which constitutes the highly 
impermeable outer lipid layer of the cell wall (Dubnau et al., 2000) is inhibited by 
isoniazid (Takayma et al., 1972). Leishmania 3-oxoacyl- acyl carrier protein 
synthase II enzyme is involved in fatty acid synthesis too. The identified 
homology suggested possible effect of isoniazid; a drug used in combination with 
rifampicin for treatment of pulmonary tuberculosis; against Leishmanaia parasite. 
Isoniazid showed significant effect (p<0.05) against Leishmania major 
amastigotes at concentrations of 0.1, 0.2 and 0.4µg/ml compared with 20µg/ml 
SSG and with the negative controls using in vitro THP infection assay. Doses of 
0.1 and 0.2µg/ml isoniazid produced lesser percentage of killings than that 
produced by 20µg/ml SSG, while dose of 0.4µg/ml produced greater percentage 
of killing (60.2%) than that produced by 20µg/ml SSG (57.6%). 
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 Isoniazid also showed significant effect (p<0.05) against Leishmania donovani 
amastigotes at concentrations of 0.1, 0.2 and 0.4µg/ml compared with 24µg/ml 
SSG and with the negative controls using in vitro THP infection assay. But the 
three concentrations produced lesser percentage of killing (52.8, 54.3 and 58.8%) 
than that produced by 24µg/ml SSG and greater than that on Leishmania major 
produced by the same dose suggesting isoniazid to be more active against 
Leishmania donovani amastigotes.  
A previous report (Berman and Lee, 1983) showed an antileshmainial effect of 
isoniazid.  It was tested in combination with rifampicin against Leishmania 
tropica within human macrophages in vitro and it produced 40% parasite 
elimination.  
A synergistic effect of INH and SSG against Leishmania major amastigotes was 
evident by the increase in the percentage of killing from 34.7, 42.4 and 61.2% to 
72.8, 77.7 and 83.8% when the two drugs were added together to the test cultures. 
This synergistic effect was evident by little increase in the percentage of killing of 
Leishmania donovani amastigotes from 50.7, 53.3 and 57.1% to 60.8, 69.5 and 
72.3% encouraging the use of SSG plus isoniazid for invivo treatment of 
leishmaniasis. 
 Another synergism was obtained when INH and amBisome were added together. 
This was evident by the increase in the percentage of killing of Leishmania major 
amastigotes from 30.3, 38.5 and 45.3% to 64.8, 70.6 and 77.1% and the 
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percentage of killing of Leishmania donovani amastigotes from 48.0, 52.0 and 
55.3% to 67.9, 70.4 and 75.2% when the two drugs were added together to the test 
cultures suggesting administration of INH together with amBisome could 
eliminate more parasite than amBisome alone. 
Addition of SSG to isoniazid produced more increase in the percentage of killing 
of both amastigotes of Leishmania major and Leishmania donovani as compared 
to that produced by addition of amBisome to isoniazid. 
Alignment of dihydrofolate reductase-thymidylate synthase of plasmodium 
falciparum and Leishmania donovani showed 53% maximum identities, while 
with that of plasmodium vivax showed 52% maximum identities. Alignment of 
dihydrofolate reductase-thymidylate synthase of plasmodium falciparum and 
Leishmania major showed 53% maximum identities, while with that of 
plasmodium vivax showed only 27% maximum identities. This bifunctional 
enzyme catalyses the reduction of folate to dihydrofolat and subsequently to 
tetrahydrofolate (Beverley, 1991: Webber and Whiteley, 1985).   
Pyrimethamine plus sulfadoxine produces marked activity reduction in the 
promastigotes. But it was less active against leishmania amastigotes (less than 
41% percentage of killing in both Leishmania major and Leishmania donovani 
amastigotes) compared to SSG. Previous report (De Carvalho et al., 2003) 
showed antileshmainial effect of targeted drugs of pyrimethamine such as 
carboxymethyldextranthio-mannopyranoside pyrimethamine. It was tested at dose 
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of 4.86µg/ml pyrimethamine against Leishmania amzonensis amastigotes within 
human macrophages in vitro and it produced 50% destruction of intracellular 
amastigotes.  
Pyrimethamine sulfadoxine combination is capable of inhibition of dihydrofolate 
rteductase thymidylate synthase (DHFR? TS) which catalyses the production of 
tetrahydrofolate and dTMP which are crucial for pyrimidine biosynthesis. The 
less activity of this antifolate may be due to pteridine reductase 1(PTR1), a novel 
leishmania enzyme responsible for salvage of pteridine, it catalyses the reduction 
of conjugated and unconjugated pterins and it can carry out the reduction of folate 
to dihydro and tetrahydrofolate (Nare et al., 1997). Hence PTR1 is much less 
sensitive to sulfadoxine than DHFR–TS (Bello et al., 1994); it can provide a 
metabolic by pass to the blocked DHFR–TS and mediates antifolate resistance 
although it is inhibited by pyrimethamine but this effect is produced in high 
concentration. 
The effect of isoniazid alone and in combination with SSG or amBisome is very 
promising and this should be further evaluated. Isoniazid plus SSG or amBisome 
could lead to reduction in the treatment course hence isoniazid is a safe drug and 
already in use for the treatment of pulmonary tuberculosis. Isoniazid is safe, 
affordable and administered orally and could be used in Combination to enhance 
the cure and prevent the emergence of drug resistance. 
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Conclusion 
· Isoniazid, the anti tuberculus drug, has antileishmanial activity at 0.1, 0.2 
and 0.4µg/ml concentrations in vitro. 
·   The antileishmanial activity of sodium stibogluconate is synergistically 
increased by isoniazid. 
· The antileishmanial activity of liposomal amphotericin B is synergistically 
increased by isoniazid. 
· Sulfadoxine pyrimethamine combination has minimum antileishmanial 
activity at 1.9 pyrimethamine and 38.1 sulfadoxine, 2.9 pyrimethamine 
and 57.1sulfadoxine, 3.8 pyrimethamine and 76.2sulfadoxine 
concentrations in vitro.  
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Recommendations 
· Evaluation of the antileishmanial activity of isoniazid alone and in 
combination with sodium stibogluconate or amBisome in vivo. 
· Evaluation of the antileishmanial activity of Sulfadoxine pyrimethamine 
combination using higher concentration in vitro.  
·  Evaluation of the antileishmanial activity of Sulfadoxine pyrimethamine 
combination in vivo.  
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Appendix 1 
ůŝŐŶŵĞŶƚŽĨůĞŝƐŚŵĂŶŝĂŵĂũŽƌϯ-oxoacyl- acyl carrier protein synthase¡¡ and 
mycobacterium fatty acid synthase 
Score = 55.5 bits (132), Expect = 3e-11, Method: Compositional 
matrix adjust. 
 Identities = 87/322 (27%), Positives = 130/322 (40%), Gaps = 
43/322 (13%) 
Query  157   GQVYYSKVPPMFLPKILGNMAAGNTAIRHKLRGPIGSS------
VAACATGAHCIGEAAS  210 
             G +     P     ++L N+ A      H ++  +GS       VAACAT A  
+ E    
Sbjct  2678  GNLLGRNKPNDIFQEVLPNIIAA-----
HVVQSYVGSYGAMIHPVAACATAAVSVEEGVD  2732 
Query  211   WIREGRADVMVCGAAEACITPVSVAGFTRMRA------
LCTRYNETPSSASRPLDITRAG  264 
              IR G+A ++V G  +  +T   + GF  M A      +C R     S  
SRP D  R G 
Sbjct  2733  KIRLGKAQLVVAGGLD-DLTLEGIIGFGDMAATADTSMMCGR-
GIHDSKFSRPNDRRRLG  2790 
Query  265   FVMGEGAGVLILEALEHAVARAAP--
RVYAELRGFGISCDAHHVAVPHPDGLGARRC---  319 
             FV  +G G ++L   + A+    P   V A  + FG   D  H ++P P            
Sbjct  2791  FVEAQGGGTILLARGDLALRMGLPVLAVVAFAQSFG---
DGVHTSIPAPGLGALGAGRGG  2847 
Query  320   ----
VEQALADGGDVPATAVGYVNAHATGTIGDEVELMAIQRALRPSTAPSSTA-LHVSS  374 
                 + +ALA  G V A  V  ++ H T T+ ++     +   L  +   S  
A L V S 
Sbjct  2848  KDSPLARALAKLG-
VAADDVAVISKHDTSTLANDPNETELHERLADALGRSEGAPLFVVS  2906 
 
Query  375   AKGGLGHLLGAAGSVEAALTVLALHEQRAPPTANLTTSCLTKEQQDCG-
LVCIQGS----  429 
              K   GH  G A   +       L +   PP  N +  C+  E       V 
++ +     
Sbjct  2907  QKSLTGHAKGGAAVFQMMGLCQILRDGVIPP--
NRSLDCVDDELAGSAHFVWVRDTLRLG  2964 
 
Query  430   AAQPLQSCEAAISTSFGFGGIN  451 
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                PL+   A + TS GFG ++ 
Sbjct  2965  GKFPLK---AGMLTSLGFGHVS  2983 
 
 Score = 23.1 bits (48),  Expect = 0.13, Method: Compositional 
matrix adjust. 
 Identities = 21/72 (29%), Positives = 32/72 (44%), Gaps = 2/72 
(3%) 
Query  350   VELMAIQRALRPSTAPSSTALHVSSAKGGLGHLLGAAGSVEAALTV--
LALHEQRAPPTA  407 
             +EL+A Q A       +   L +  A GGLG        V+++ TV  LA +  
+ P  A 
Sbjct  1650  
IELLAWQFASPVRWIETQDLLFIEEAAGGLGVERFVEIGVKSSPTVAGLATNTLKLPEYA  
1709 
Query  408   NLTTSCLTKEQQ  419 
             + T   L  E+  
Sbjct  1710  HSTVEVLNAERD  1721 
 
 Score = 20.4 bits (41),  Expect = 0.97, Method: Compositional 
matrix adjust. 
 Identities = 10/15 (67%), Positives = 10/15 (67%), Gaps = 2/15 
(13%) 
 
Query  228  CITP--VSVAGFTRM  240 
            CI P   SVAG TRM 
Sbjct  876  CIIPGTASVAGITRM  890 
 
 Score = 18.1 bits (35),  Expect = 4.6, Method: Compositional 
matrix adjust. 
 Identities = 11/34 (32%), Positives = 20/34 (59%), Gaps = 1/34 
(3%) 
Query  379  LGHLLGAAGSVEAALTVLALHEQRAPPTANLTTS  412 
            L  L+GAAG++ A    +++   R PP  ++T + 
Sbjct  171  LAQLIGAAGTLVARRRGISVLGDR-PPMVSVTNA  203 
 
 Score = 17.3 bits (33),  Expect = 8.3, Method: Compositional 
matrix adjust. 
 Identities = 9/18 (50%), Positives = 11/18 (61%), Gaps = 0/18 
(0%) 
 
Query  268  GEGAGVLILEALEHAVAR  285 
            G   GVL +EAL+   AR 
Sbjct  147  GHSQGVLAVEALKAGGAR  164 
 
 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
 ϭϬϲ 
 
 
ůŝŐŶŵĞŶƚŽĨůĞŝƐŚŵĂŶŝĂĚŽŶŽǀĂŶŝϯ-oxoacyl- acyl carrier protein synthase¡¡ 
and mycobacterium fatty acid synthase 
Score = 54.7 bits (130), Expect = 5e-11, Method: Compositional 
matrix adjust. 
 Identities = 79/284 (28%), Positives = 119/284 (42%), Gaps = 
37/284 (13%) 
Query  157   GHVHYSKVPPMFLPKILGNMAAGNTAIRHKLRGPIGSS------
VAACATGAHCIGEAAL  210 
             G++     P     ++L N+ A      H ++  +GS       VAACAT A  
+ E    
Sbjct  2678  GNLLGRNKPNDIFQEVLPNIIAA-----
HVVQSYVGSYGAMIHPVAACATAAVSVEEGVD  2732 
Query  211   WIREGRADVMVCGAAEACITPVSVAGFTRMRA------LCTR-
FNDTPSSASRPFDITRA  263 
              IR G+A ++V G  +  +T   + GF  M A      +C R  +D  S  
SRP D  R  
Sbjct  2733  KIRLGKAQLVVAGGLD-DLTLEGIIGFGDMAATADTSMMCGRGIHD--
SKFSRPNDRRRL  2789 
Query  264   GFVMGEGAGVLILEALEHAVARAAP--
RVYAELRGFGISCDAHHVAVPHPEGLGARRC--  319 
             GFV  +G G ++L   + A+    P   V A  + FG   D  H ++P P           
Sbjct  2790  GFVEAQGGGTILLARGDLALRMGLPVLAVVAFAQSFG---
DGVHTSIPAPGLGALGAGRG  2846 
Query  320   -----
VEQALAEGGDVPASAVGYVNAHATGTIGDEVELMAIQQALRPSTAPSSPA-LHVS  373 
                  + +ALA+ G V A  V  ++ H T T+ ++     + + L  +   S  
A L V  
Sbjct  2847  GKDSPLARALAKLG-
VAADDVAVISKHDTSTLANDPNETELHERLADALGRSEGAPLFVV  2905 
 
Query  374   SAKGGLGHLLGAAGSVEAALTVLALHEQRAPPTANLTTSCLTRE  417 
             S K   GH  G A   +       L +   PP  N +  C+  E 
Sbjct  2906  SQKSLTGHAKGGAAVFQMMGLCQILRDGVIPP--NRSLDCVDDE  2947 
 
 Score = 22.3 bits (46),  Expect = 0.23, Method: Compositional 
matrix adjust. 
 Identities = 21/72 (29%), Positives = 32/72 (44%), Gaps = 2/72 
(3%) 
Query  350   VELMAIQQALRPSTAPSSPALHVSSAKGGLGHLLGAAGSVEAALTV--
LALHEQRAPPTA  407 
             +EL+A Q A       +   L +  A GGLG        V+++ TV  LA +  
+ P  A 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
 ϭϬϳ 
 
Sbjct  1650  
IELLAWQFASPVRWIETQDLLFIEEAAGGLGVERFVEIGVKSSPTVAGLATNTLKLPEYA  
1709 
Query  408   NLTTSCLTREQQ  419 
             + T   L  E+  
Sbjct  1710  HSTVEVLNAERD  1721 
 
 Score = 20.4 bits (41),  Expect = 0.81, Method: Compositional 
matrix adjust. 
 Identities = 13/27 (48%), Positives = 13/27 (48%), Gaps = 6/27 
(22%) 
Query  228  CITP--VSVAGFTRMR----ALCTRFN  248 
            CI P   SVAG TRM      L  RF  
Sbjct  876  CIIPGTASVAGITRMDEPVGELLDRFE  902 
 
 Score = 18.1 bits (35),  Expect = 4.1, Method: Compositional 
matrix adjust. 
 Identities = 11/34 (32%), Positives = 20/34 (59%), Gaps = 1/34 
(3%) 
Query  379  LGHLLGAAGSVEAALTVLALHEQRAPPTANLTTS  412 
            L  L+GAAG++ A    +++   R PP  ++T + 
Sbjct  171  LAQLIGAAGTLVARRRGISVLGDR-PPMVSVTNA  203 
 
 Score = 17.3 bits (33),  Expect = 8.1, Method: Compositional 
matrix adjust. 
 Identities = 9/18 (50%), Positives = 11/18 (61%), Gaps = 0/18 
(0%) 
Query  268  GEGAGVLILEALEHAVAR  285 
            G   GVL +EAL+   AR 
Sbjct  147  GHSQGVLAVEALKAGGAR  164 
 
 
 
 
 
 
 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
 ϭϬϴ 
 
Alignment of dihydrofolate reductase-thymidylate synthase [Leishmania 
major] and dihydrofolate reductase-thymidylate synthase [Plasmodium 
falciparum] 
Score = 341 bits (875), Expect = 4e-98, Method: Compositional 
matrix adjust. 
 Identities = 153/288 (53%), Positives = 205/288 (71%), Gaps = 
3/288 (1%) 
 
Query  232  
HEERQYLELIDRIMKTGIVKEDRTGVGTISLFGAQMRFSLRDNRLPLLTTKRVFWRGVCE  291 
            H E QYL +I  IM  G  + DRTGVG +S FG  M+F L     
PLLTTK++F RG+ E 
Sbjct  323  HPEYQYLNIIYDIMMNGNKQSDRTGVGVLSKFGYIMKFDLSQ-
YFPLLTTKKLFLRGIIE  381 
 
Query  292  
ELLWFLRGETSAQLLADKDIHIWDGNGSREFLDSRGLTENKEMDLGPVYGFQWRHFGADY  351 
            ELLWF+RGET+   L +K++ IW+ NG+REFLD+R L   +  
DLGP+YGFQWRHFGA+Y 
Sbjct  382  
ELLWFIRGETNGNTLLNKNVRIWEANGTREFLDNRKLFHREVNDLGPIYGFQWRHFGAEY  441 
 
Query  352  
KGFEANYDGEGVDQIKLIVETIKTNPNDRRLLVTAWNPCALQKMALPPCHLLAQFYVNTD  411 
                 NY+ +GVDQ+K I+  IK +P  RR+L+ AWN   L +MALPPCH+L 
QFYV    
Sbjct  442  
TNMYDNYENKGVDQLKNIINLIKNDPTSRRILLCAWNVKDLDQMALPPCHILCQFYV--F  499 
 
Query  412  
TSELSCMLYQRSCDMGLGVPFNIASYALLTILIAKATGLRPGELVHTLGDAHVYRNHVDA  471 
              +LSC++YQRSCD+GLGVPFNIASY++ T +IA+   L+P + +H 
LG+AHVY NH+D+ 
Sbjct  500  
DGKLSCIMYQRSCDLGLGVPFNIASYSIFTHMIAQVCNLQPAQFIHVLGNAHVYNNHIDS  559 
 
Query  472  LKAQLERVPHAFPTLIFKEERQYLEDYELTDMEVIDYVPHPAIKMEMA  519 
            LK QL R+P+ FPTL    + + +ED+ ++D  + +YV H  I M+MA 
Sbjct  560  LKIQLNRIPYPFPTLKLNPDIKNIEDFTISDFTIQNYVHHEKISMDMA  607 
 
 Score = 76.6 bits (187), Expect = 2e-18, Method: Compositional 
matrix adjust. 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
 ϭϬϵ 
 
 Identities = 60/213 (28%), Positives = 93/213 (44%), Gaps = 
48/213 (23%) 
Query  38   GIGDGESIPWRVPE-DMTFFKNQTTLLR-----------------------
NKKPPTEKK  73 
            G+G+   +PW+    DM +F   TT +                        N  
P ++K  
Sbjct  39   
GLGNKGVLPWKCNSLDMKYFCAVTTYVNESKYEKLKYKRCKYLNKETVDNVNDMPNSKKL  98 
Query  74   
RNAVVMGRKTWESVPVKFRPLKGRLNIVLSSKATVEELLAPLPEGQRAAAAQDVVVVNGG  133 
            +N VVMGR  WES+P KF+PL  R+N++LS     E+              
+DV ++N   
Sbjct  99   QNVVVMGRTNWESIPKKFKPLSNRINVILSRTLKKEDF------------
DEDVYIIN-K  145 
Query  134  
LAEALRLLARPLYCSSIETAYCVGGAQVYADAMLSPCIEKLQEVYLTRIYATAPACTRFF  193 
            + + + LL +  Y       + +GG+ VY + +    I+K   +Y TRI +T   
C  FF 
Sbjct  146  VEDLIVLLGKLNY----YKCFIIGGSVVYQEFLEKKLIKK---
IYFTRINSTY-ECDVFF  197 
 
Query  194  PFPPENAATAWDLASSQGRRKSEAEGLEFEICK  226 
            P   EN    + + S      S    L+F I K 
Sbjct  198  PEINEN---EYQIISVSDVYTSNNTTLDFIIYK  227 
 
 Score = 18.9 bits (37),  Expect = 0.58, Method: Compositional 
matrix adjust. 
 Identities = 7/19 (37%), Positives = 12/19 (63%), Gaps = 2/19 
(11%) 
Query  400  CHL--LAQFYVNTDTSELS  416 
            CH+  L +FY N D  +++ 
Sbjct  259  CHMKKLTEFYKNVDKYKIN  277 
 
 Score = 16.9 bits (32),  Expect = 2.2, Method: Compositional 
matrix adjust. 
 Identities = 6/20 (30%), Positives = 11/20 (55%), Gaps = 0/20 
(0%) 
Query  82   KTWESVPVKFRPLKGRLNIV  101 
            + + S+  K+ P    LNI+ 
Sbjct  313  QIYNSLKYKYHPEYQYLNII  332 
 
 
 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
 ϭϭϬ 
 
Alignment of dihydrofolate reductase-thymidylate synthase [Leishmania 
major] and dihydrofolate reductase-thymidylate synthase [Plasmodium vivax] 
Score = 65.1 bits (157), Expect = 2e-15, Method: Compositional 
matrix adjust. 
 Identities = 49/187 (27%), Positives = 81/187 (44%), Gaps = 
50/187 (26%) 
 
Query  37   HGIGDGESIPWRVPE-DMTFFKNQTTLLRNKK---------------------
-------  67 
             G+G+  ++PW+    DM +F++ TT +   K                             
Sbjct  37   
RGLGNKGTLPWKCNSVDMKYFRSVTTYVDESKYEKLKWKRERYLRMEASQGGGDNTSGGD  96 
 
Query  68   
PPTEKKRNAVVMGRKTWESVPVKFRPLKGRLNIVLSSKATVEELLAPLPEGQRAAAAQDV  127 
               +K +N VVMGR  WES+P +++PL  R+N+VLS   T E++             
+ V 
Sbjct  97   NNADKLQNVVVMGRSNWESIPKQYKPLPNRINVVLSKTLTKEDV---------
---KEKV  144 
 
Query  128  
VVVNGGLAEALRLLARPLYCSSIETAYCVGGAQVYADAMLSPCIEKLQEVYLTRIYATAP  187 
             ++     +++  L   L        + +GGAQVY + +    I   +++Y 
TRI    P 
Sbjct  145  FII-----DSIDDLLLLLKKLKYYKCFIIGGAQVYRECLSRNLI---
KQIYFTRINGAYP  196 
 
Query  188  ACTRFFP  194 
             C  FFP 
Sbjct  197  -CDVFFP  202 
 
 
 
 
 
 
 
 
 
 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
 ϭϭϭ 
 
Alignment of dihydrofolate reductase-thymidylate synthase [Leishmania 
donovani] and dihydrofolate reductase-thymidylate synthase [Plasmodium 
falciparum] 
Score =  340 bits (871),  Expect = 1e-97, Method: Compositional 
matrix adjust. 
 Identities = 152/288 (53%), Positives = 204/288 (71%), Gaps = 
3/288 (1%) 
 
Query  232  
HEERQYLELIDRIMKTGIVKEDRTGVGTISLFGAQMRFSLRDNRLPLLTTKRVFWRGVCE  291 
            H E QYL +I  IM  G  + DRTGVG +S FG  M+F L     
PLLTTK++F RG+ E 
Sbjct  323  HPEYQYLNIIYDIMMNGNKQSDRTGVGVLSKFGYIMKFDLSQ-
YFPLLTTKKLFLRGIIE  381 
 
Query  292  
ELLWFLRGETNAQLLADKDIHIWDGNGSREFLDSRGLTENKEMDLGPVYGFQWRHFGADY  351 
            ELLWF+RGETN   L +K++ IW+ NG+REFLD+R L   +  
DLGP+YGFQWRHFGA+Y 
Sbjct  382  
ELLWFIRGETNGNTLLNKNVRIWEANGTREFLDNRKLFHREVNDLGPIYGFQWRHFGAEY  441 
 
Query  352  
KGFEANYDGEGVDQIRSIVETIKANPNDRRLLFTAWNPCALQKMALPPCHLLAQFYVNTD  411 
                 NY+ +GVDQ+++I+  IK +P  RR+L  AWN   L +MALPPCH+L 
QFYV    
Sbjct  442  
TNMYDNYENKGVDQLKNIINLIKNDPTSRRILLCAWNVKDLDQMALPPCHILCQFYV--F  499 
 
Query  412  
TSELSCMLYQRSCDMGLGVPFNIASYALLTILIAKATGLRPGELVHTLGDAHVYRNHVGA  471 
              +LSC++YQRSCD+GLGVPFNIASY++ T +IA+   L+P + +H 
LG+AHVY NH+ + 
Sbjct  500  
DGKLSCIMYQRSCDLGLGVPFNIASYSIFTHMIAQVCNLQPAQFIHVLGNAHVYNNHIDS  559 
 
Query  472  LKSQLERVPHAFPTLVFKEERQFLEDYELTDMEVIDYVPHPPIKMEMA  519 
            LK QL R+P+ FPTL    + + +ED+ ++D  + +YV H  I M+MA 
Sbjct  560  LKIQLNRIPYPFPTLKLNPDIKNIEDFTISDFTIQNYVHHEKISMDMA  607 
 
 
 Score = 77.0 bits (188),  Expect = 2e-18, Method: Compositional 
matrix adjust. 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
 ϭϭϮ 
 
 Identities = 59/213 (28%), Positives = 93/213 (44%), Gaps = 
48/213 (23%) 
Query  38   GIGDGESIPWRVPE-DMAFFKDQTTLLR-----------------------
NKKPPTEKK  73 
            G+G+   +PW+    DM +F   TT +                        N  
P ++K  
Sbjct  39   
GLGNKGVLPWKCNSLDMKYFCAVTTYVNESKYEKLKYKRCKYLNKETVDNVNDMPNSKKL  98 
Query  74   
RNAVVMGRKTWESVPVKFRPLKGRLNIVLSSKATVEELLAPLPEGKRAAAAQDVVVVNDG  133 
            +N VVMGR  WES+P KF+PL  R+N++LS     E+              
+DV ++N   
Sbjct  99   QNVVVMGRTNWESIPKKFKPLSNRINVILSRTLKKEDF------------
DEDVYIIN-K  145 
Query  134  
LAEALRLLARPPYCSSIETAYCVGGAQVYADAMLSPCVEKLQEVYLTRIYTTAPACTRFF  193 
            + + + LL +  Y       + +GG+ VY + +    ++K   +Y TRI +T   
C  FF 
Sbjct  146  VEDLIVLLGKLNY----YKCFIIGGSVVYQEFLEKKLIKK---
IYFTRINSTY-ECDVFF  197 
Query  194  PFPPENTTTAWDLASSQGRRKSEADGLEFEICK  226 
            P   EN    + + S      S    L+F I K 
Sbjct  198  PEINEN---EYQIISVSDVYTSNNTTLDFIIYK  227 
 
 Score = 18.9 bits (37),  Expect = 0.58, Method: Compositional 
matrix adjust. 
 Identities = 7/19 (37%), Positives = 12/19 (63%), Gaps = 2/19 
(11%) 
 
Query  400  CHL--LAQFYVNTDTSELS  416 
            CH+  L +FY N D  +++ 
Sbjct  259  CHMKKLTEFYKNVDKYKIN  277 
 
 Score = 16.9 bits (32),  Expect = 2.1, Method: Compositional 
matrix adjust. 
 Identities = 6/20 (30%), Positives = 11/20 (55%), Gaps = 0/20 
(0%) 
Query  82   KTWESVPVKFRPLKGRLNIV  101 
            + + S+  K+ P    LNI+ 
Sbjct  313  QIYNSLKYKYHPEYQYLNII  332 
 
 
 
 
 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
 ϭϭϯ 
 
Alignment of dihydrofolate reductase-thymidylate synthase [Leishmania 
donovani] and dihydrofolate reductase-thymidylate synthase [Plasmodium 
vivax] 
Score =  332 bits (851),  Expect = 3e-95, Method: Compositional 
matrix adjust. 
 Identities = 151/290 (52%), Positives = 205/290 (71%), Gaps = 
3/290 (1%) 
 
Query  230  
RNHEERQYLELIDRIMKTGIVKEDRTGVGTISLFGAQMRFSLRDNRLPLLTTKRVFWRGV  289 
            + H E QYL +I  I+  G  + DRTGVG +S FG  M+F+L +   
PLLTTK++F RG+ 
Sbjct  331  KQHPEYQYLGIIYDIIMNGNKQGDRTGVGVMSKFGYMMKFNLSE-
YFPLLTTKKLFLRGI  389 
 
Query  290  
CEELLWFLRGETNAQLLADKDIHIWDGNGSREFLDSRGLTENKEMDLGPVYGFQWRHFGA  349 
             EELLWF+RGETN   L +K++ IW+ NG+REFLD+R L   +  
DLGP+YGFQWRHFGA 
Sbjct  390  
IEELLWFIRGETNGNTLLNKNVRIWEANGTREFLDNRKLFHREVNDLGPIYGFQWRHFGA  449 
 
Query  350  
DYKGFEANYDGEGVDQIRSIVETIKANPNDRRLLFTAWNPCALQKMALPPCHLLAQFYVN  409 
            +Y     NY+ +GVDQ+++++  IK  P  RR++  AWN   L +MAL 
PCH+L QFYV  
Sbjct  450  
EYTNMHDNYEDKGVDQLKNVIHLIKNEPTSRRIILCAWNVKDLDQMALLPCHILCQFYV-  508 
 
Query  410  
TDTSELSCMLYQRSCDMGLGVPFNIASYALLTILIAKATGLRPGELVHTLGDAHVYRNHV  469 
                +LSC++YQRSCD+GLGVPFNIASY++ T +IA+   L+P + +H 
LG+AHVY NHV 
Sbjct  509  -
FDGKLSCIMYQRSCDLGLGVPFNIASYSIFTHMIAQVCNLQPAQFIHILGNAHVYNNHV  567 
 
Query  470  GALKSQLERVPHAFPTLVFKEERQFLEDYELTDMEVIDYVPHPPIKMEMA  
519 
             +LK QL R+P+ FPTL    E + +ED+ ++D  + +YV H  I MEMA 
Sbjct  568  DSLKVQLNRIPYPFPTLKLNPEVKNIEDFTISDFTIENYVHHDKITMEMA  
617 
 
 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
 ϭϭϰ 
 
 Score = 67.4 bits (163),  Expect = 2e-15, Method: Compositional 
matrix adjust. 
 Identities = 51/185 (28%), Positives = 82/185 (44%), Gaps = 
49/185 (26%) 
 
Query  38   GIGDGESIPWRVPE-DMAFFKDQTTLLRNKK----------------------
-----PP  69 
            G+G+  ++PW+    DM +F   TT +   K                              
Sbjct  38   
GLGNKGTLPWKCNSVDMKYFSSVTTYVDESKYEKLKWKRERYLRMEASQGGGDNTSGGDN  97 
 
Query  70   
TEKKRNAVVMGRKTWESVPVKFRPLKGRLNIVLSSKATVEELLAPLPEGKRAAAAQDVVV  129 
             +K +N VVMGR +WES+P +++PL  R+N+VLS   T EE+             
++ V  
Sbjct  98   ADKLQNVVVMGRSSWESIPKQYKPLPNRINVVLSKTLTKEEV-----------
--KEKVF  144 
 
Query  130  
VNDGLAEALRLLARPPYCSSIETAYCVGGAQVYADAMLSPCVEKLQEVYLTRIYTTAPAC  189 
            + D + + L LL +          + +GGAQVY + +    +   +++Y TRI    
P C 
Sbjct  145  IIDSIDDLLLLLKK----LKYYKCFIIGGAQVYRECLSRNLI---
KQIYFTRINGAYP-C  196 
 
Query  190  TRFFP  194 
              FFP 
Sbjct  197  DVFFP  201 
 
 
 
 
 
 
 
 
 
 
 
 
Please purchase PDFcamp Printer on http://www.verypdf.com/ to remove this watermark.
